[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_1dc44e34-d327-4d90-88d3-5e6ba5b5bd73":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:1dc44e34-d327-4d90-88d3-5e6ba5b5bd73,\"}":91},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":33,"indexDatabases":55,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},"1dc44e34-d327-4d90-88d3-5e6ba5b5bd73","2023-12-05T06:46:18.654+00:00","2025-11-21T09:48:40.258+00:00",[],"Trends-in-Pharmacological-Sciences",{"issn":12,"title":14},{"VOID":13},"01656147",{"EN":15},"Trends in Pharmacological Sciences","PUBLISHER","PENDING",null,0,[21,27],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":23,"label":24,"description":26,"parentId":18,"standard":18,"scholarHubFieldId":18},"304614db-b5ea-4999-9a2b-b6cb83b4488a",[],{"EN":25},"Toxicology",{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":29,"label":30,"description":32,"parentId":18,"standard":18,"scholarHubFieldId":18},"8b51d244-613f-4ff9-b308-d32de7c33ed9",[],{"EN":31},"Pharmacology",{},[34,41,48],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":36,"slug":18,"properties":37,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":40,"statistic":18},"c2e41d78-81a3-4816-9373-40b87f073997",[],{"title":38},{"EN":39},"ELSEVIER SCIENCE LONDON",[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":43,"slug":18,"properties":44,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":47,"statistic":18},"a4a936f8-3ebf-415c-94f9-5c50afa26a67",[],{"title":45},{"EN":46},"Cell Press",[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":50,"slug":18,"properties":51,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":54,"statistic":18},"cbc888ff-f0a8-49ab-90e6-8acb752d4f88",[],{"title":52},{"EN":53},"Elsevier Ltd.",[],[56,73],{"id":57,"indexDatabase":58,"url":70,"indexYears":18,"academicFieldIds":71,"indexDatabaseRanking":18},"543eb58e-6cc4-4123-8bce-195c91ca6618",{"id":59,"createTime":18,"updateTime":18,"relativeEntities":60,"label":61,"description":63,"key":66,"publicationTags":67,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":62,"VI":62},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":64,"VI":65},"SCIE database","Cơ sở dữ liệu SCIE","scie",[68,69],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0165-6147",[72],"2b943d65-24a8-4546-9232-a1e32c12cb6c",{"id":74,"indexDatabase":75,"url":85,"indexYears":86,"academicFieldIds":87,"indexDatabaseRanking":90},"5fc38595-fcdf-414d-85dc-17a88c314a5e",{"id":76,"createTime":18,"updateTime":18,"relativeEntities":77,"label":78,"description":80,"key":82,"publicationTags":83,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":79,"VI":79},"Scopus - Elsevier",{"EN":79,"VI":81},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[84],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F22321","1979-2025",[88,89],"efd4c2fb-aeaa-4e42-8995-94fc907aae70","e39d1b91-b03d-48ed-87bb-ab5b714ad558","SCOPUS__Q1",{"meta":92,"data":94},{"total":93},"2026",[95,240,355,708,910,1415,1535,1663,1779,1868],{"id":96,"createTime":97,"updateTime":98,"relativeEntities":99,"slug":100,"properties":101,"entityType":110,"verifyStatus":111,"verifyTime":112,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":114,"fullTextUrl":18,"authors":115,"publicationType":180,"publisherRelationship":181,"citationCount":19,"citationInfo":232,"publishDate":235,"publishYear":233,"citationAnalyzeStatus":236,"lastCitationAnalyze":237,"indexDatabases":238,"openAccess":18,"references":18,"isForceReanalyzing":239},"b785626b-d2dc-42d1-80ec-0ecfbe830c26","2024-02-08T05:04:26.851+00:00","2026-08-24T17:54:25.078+00:00",[],"Treating-brain-tumors-with-PDE4-inhibitors",{"title":102,"gsPaper":104,"references":106,"doi":108},{"EN":103},"Treating brain tumors with PDE4 inhibitors",{"VOID":105},"[\"10482039142684426027\"]",{"VOID":107},"Sutherland, 1971, [Nobel prize in physiology or medicine 1971: the action of hormones outlined], Lakartidningen, 68, 4991\nSavai, 2010, Targeting cancer with phosphodiesterase inhibitors, Expert Opin. Investig. Drugs, 19, 117, 10.1517\u002F13543780903485642\nFurman, 1977, Cyclic AMP and adenyl cyclase in brain tumors, J. Neurosurg., 46, 477, 10.3171\u002Fjns.1977.46.4.0477\nWarrington, 2007, Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1, Cancer Res., 67, 8588, 10.1158\u002F0008-5472.CAN-06-2220\nYang, 2007, Blocking CXCR4-Mediated Cyclic AMP Suppression Inhibits Brain Tumor Growth In vivo, Cancer Res., 67, 651, 10.1158\u002F0008-5472.CAN-06-2762\nChen, 2002, The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells, Cancer Biol. Ther., 1, 268, 10.4161\u002Fcbt.80\nSchmidt, 2009, BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells, J. Mol. Neurosci., 40, 303, 10.1007\u002Fs12031-009-9221-8\nLelievre, 2008, Disruption of the Pacap gene promotes medulloblastoma in ptc1 mutant mice, Dev. Biol., 313, 359, 10.1016\u002Fj.ydbio.2007.10.031\nLiu, 2010, Induction of cell cycle arrest at G1 and S phases and cAMP-dependent differentiation in C6 glioma by low concentration of cycloheximide, BMC Cancer, 10, 684, 10.1186\u002F1471-2407-10-684\nRubin, 2005, Neurofibromatosis type 1 – a model for nervous system tumour formation?, Nat. Rev. Cancer, 5, 557, 10.1038\u002Fnrc1653\nWarrington, 2010, Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1, Cancer Res., 70, 5717, 10.1158\u002F0008-5472.CAN-09-3769\nHuston, 2006, cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling, Biochem. Soc. Trans., 34, 504, 10.1042\u002FBST0340504\nKeravis, 2010, Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs, Curr. Pharm. Des., 16, 1114, 10.2174\u002F138161210790963760\nKelly, 2009, Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals, Prog. Brain Res., 179, 67, 10.1016\u002FS0079-6123(09)17908-6\nItoh, 2009, PET measurement of the in vivo affinity of 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats, J. Nucl. Med., 50, 749, 10.2967\u002Fjnumed.108.058305\nZhang, 2009, Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs, Curr. Pharm. Des., 15, 1688, 10.2174\u002F138161209788168092\nSiuciak, 2008, The role of phosphodiesterases in schizophrenia: therapeutic implications, CNS Drugs, 22, 983, 10.2165\u002F0023210-200822120-00002\nBraun, 2007, Expression of phosphodiesterase 4 is altered in the brains of subjects with autism, Neuroreport, 18, 1841, 10.1097\u002FWNR.0b013e3282f16dca\nGoldhoff, 2008, Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression, Clin. Cancer Res., 14, 7717, 10.1158\u002F1078-0432.CCR-08-0827\nBurgin, 2010, Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety, Nat. Biotechnol., 28, 63, 10.1038\u002Fnbt.1598\nJacobitz, 1997, Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A, Mol. Pharmacol., 51, 999, 10.1124\u002Fmol.51.6.999\nRacagni, 1983, Cyclic nucleotides in experimental and human brain tumors, J. Neurooncol., 1, 61, 10.1007\u002FBF00153643\nNorthcott, 2010, Medulloblastoma comprises four distinct molecular variants, J. Clin. Oncol.\nDomanska, 2010, The chemokine network, a newly discovered target in high grade gliomas, Crit. Rev. Oncol. Hematol., 10.1016\u002Fj.critrevonc.2010.07.006\nSciume, 2010, Chemokines and glioma: invasion and more, J. Neuroimmunol., 224, 8, 10.1016\u002Fj.jneuroim.2010.05.019\nBian, 2007, Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival, Neurosurgery, 61, 570, 10.1227\u002F01.NEU.0000290905.53685.A2\nCalatozzolo, 2006, Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas, Cancer Biol. Ther., 5, 827, 10.4161\u002Fcbt.5.7.2838\nRubin, 2003, A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors, Proc. Natl. Acad. Sci. U.S.A., 100, 13513, 10.1073\u002Fpnas.2235846100\nZagzag, 2008, Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha\u002FCXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures, Am. J. Pathol., 173, 545, 10.2353\u002Fajpath.2008.071197\nKenig, 2010, Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9, Cancer Lett., 289, 53, 10.1016\u002Fj.canlet.2009.07.014\nConti, 2007, Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling, Annu. Rev. Biochem., 76, 481, 10.1146\u002Fannurev.biochem.76.060305.150444\nHouslay, 2010, Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown, Trends Biochem. Sci., 35, 91, 10.1016\u002Fj.tibs.2009.09.007\nKleppisch, 2009, Phosphodiesterases in the central nervous system, Handb. Exp. Pharmacol., 191, 71, 10.1007\u002F978-3-540-68964-5_5\nHouslay, 2005, Keynote review: phosphodiesterase-4 as a therapeutic target, Drug Discov Today, 10, 1503, 10.1016\u002FS1359-6446(05)03622-6\nGagelin, 1994, Inhibition of G1 cyclin expression and G1 cyclin-dependent protein kinases by cAMP in an astrocytic cell line, Biochem. Biophys. Res. Commun., 205, 923, 10.1006\u002Fbbrc.1994.2753\nBalmanno, 2003, DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry, Mol. Cell. Biol., 23, 9303, 10.1128\u002FMCB.23.24.9303-9317.2003\nHill, 2009, Identification of secreted proteins regulated by cAMP in glioblastoma cells using glycopeptide capture and label-free quantification, Proteomics, 9, 535, 10.1002\u002Fpmic.200800257\nMoreno, 2006, Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells, Glia, 53, 845, 10.1002\u002Fglia.20345\nYang, 2008, Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells, Cancer Cell, 14, 135, 10.1016\u002Fj.ccr.2008.07.003\nFila, 2009, Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)\u002Fcyclic AMP pathway that negatively regulates neuronal precursor proliferation, J. Biol. Chem., 284, 15325, 10.1074\u002Fjbc.M109.002329\nContestabile, 2005, Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells, J. Biol. Chem., 280, 33541, 10.1074\u002Fjbc.M413323200\nAhn, 2005, 8-Chloro-cyclic AMP-induced growth inhibition and apoptosis is mediated by p38 mitogen-activated protein kinase activation in HL60 cells, Cancer Res., 65, 4896, 10.1158\u002F0008-5472.CAN-04-3122\nZhang, 2004, The pro-apoptotic protein Bim is a convergence point for cAMP\u002Fprotein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells, J. Biol. Chem., 279, 20858, 10.1074\u002Fjbc.M310643200\nVitale, 2009, A new therapeutic strategy against cancer: cAMP elevating drugs and leptin, Cancer Biol. Ther., 8, 1191, 10.4161\u002Fcbt.8.12.8937\nDiPersio, 2009, Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma, J. Clin. Oncol., 27, 4767, 10.1200\u002FJCO.2008.20.7209\nBender, 2006, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use, Pharmacol. Rev., 58, 488, 10.1124\u002Fpr.58.3.5\nPress, 2009, PDE4 inhibitors – a review of the current field, Prog. Med. Chem., 47, 37, 10.1016\u002FS0079-6468(08)00202-6\nStewart, 1997, Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas, J. Neurooncol., 32, 161, 10.1023\u002FA:1005788121043\nRahrmann, 2009, Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen, Cancer Res., 69, 4388, 10.1158\u002F0008-5472.CAN-08-3901\nMeyers, 2009, Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors, J. Immunol., 182, 5400, 10.4049\u002Fjimmunol.0804255\nZhang, 2008, Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U.S.A., 105, 19532, 10.1073\u002Fpnas.0806152105\nMcEwan, 2007, Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase, Cancer Res., 67, 5248, 10.1158\u002F0008-5472.CAN-07-0097\nMurata, 2010, Expression and role of phosphodiesterase 5 in human malignant melanoma cell line, Anticancer Res., 30, 355\nBlack, 2008, PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model, Brain Res., 1230, 290, 10.1016\u002Fj.brainres.2008.06.122\nBruno, 2009, New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms, J. Med. Chem., 52, 6546, 10.1021\u002Fjm900977c\nBielekova, 2009, Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood–brain barrier disruption in multiple sclerosis, Mult. Scler., 15, 1206, 10.1177\u002F1352458509345903\nWang, 2010, Intrinsic sex-specific differences in microvascular endothelial cell phosphodiesterases, Am. J. Physiol. Heart Circ. Physiol., 298, H1146, 10.1152\u002Fajpheart.00252.2009\nDejda, 2005, Neuroprotective potential of three neuropeptides PACAP, VIP and PHI, Pharmacol. Rep., 57, 307\nThaker, 2009, Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies, Expert Rev. Neurother., 9, 1815, 10.1586\u002Fern.09.116\nKesari, 2006, Targeted molecular therapy of malignant gliomas, Curr. Oncol. Rep., 8, 58, 10.1007\u002Fs11912-006-0011-y\nDumaz, 2005, Integrating signals between cAMP and the RAS\u002FRAF\u002FMEK\u002FERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels, FEBS J., 272, 3491, 10.1111\u002Fj.1742-4658.2005.04763.x\nSomerville, 2001, Theophylline revisited, Allergy Asthma Proc., 22, 347\nHansel, 2004, Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease, Drugs Today (Barc.), 40, 55, 10.1358\u002Fdot.2004.40.1.799438\nRickles, 2010, Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies, Blood, 116, 593, 10.1182\u002Fblood-2009-11-252668\nBaillie, 2002, TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid, J. Biol. Chem., 277, 28298, 10.1074\u002Fjbc.M108353200\nKamenetsky, 2006, Molecular details of cAMP generation in mammalian cells: a tale of two systems, J. Mol. Biol., 362, 623, 10.1016\u002Fj.jmb.2006.07.045\nSadana, 2009, Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies, Neurosignals, 17, 5, 10.1159\u002F000166277\nVisel, 2006, Comprehensive analysis of the expression patterns of the adenylate cyclase gene family in the developing and adult mouse brain, J. Comp. Neurol., 496, 684, 10.1002\u002Fcne.20953\nOmori, 2007, Overview of PDEs and their regulation, Circ. Res., 100, 309, 10.1161\u002F01.RES.0000256354.95791.f1",{"VOID":109},"10.1016\u002Fj.tips.2011.02.015","PUBLICATION","VERIFIED","2024-05-16T07:00:53.378+00:00","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165614711000393",[116,134,150,164],{"id":117,"sortIndex":19,"researcher":18,"roles":118,"affiliations":120,"properties":129,"displayName":131,"givenName":18,"familyName":18},"e03bd184-d749-4d03-af63-0b134fbd1264",[119],"AUTHOR",[121],{"id":122,"sortIndex":19,"affiliation":123,"properties":18},"572cd3d1-dcf9-465d-b754-44b94709810e",{"id":122,"createTime":18,"updateTime":18,"relativeEntities":124,"slug":18,"properties":125,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":128,"statistic":18},[],{"title":126},{"VI":127},"Department of Pediatrics, Campus Box 8208, 660 South Euclid Ave, Washington University School of Medicine, St Louis, MO 63110, USA",[],{"title":130,"gsAuthor":132},{"VI":131},"Rajarshi Sengupta",{"VOID":133},"[\"kJWq4ewAAAAJ\"]",{"id":135,"sortIndex":136,"researcher":18,"roles":137,"affiliations":138,"properties":145,"displayName":147,"givenName":18,"familyName":18},"5a2cec40-10ac-48ea-bd6f-892957da4267",1,[119],[139],{"id":122,"sortIndex":19,"affiliation":140,"properties":18},{"id":122,"createTime":18,"updateTime":18,"relativeEntities":141,"slug":18,"properties":142,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":144,"statistic":18},[],{"title":143},{"VI":127},[],{"title":146,"gsAuthor":148},{"VI":147},"Tao Sun",{"VOID":149},"[\"2fWh2iEAAAAJ\"]",{"id":151,"sortIndex":152,"researcher":18,"roles":153,"affiliations":154,"properties":161,"displayName":163,"givenName":18,"familyName":18},"9e7dac5d-b999-4504-a414-622d23f79990",2,[119],[155],{"id":122,"sortIndex":19,"affiliation":156,"properties":18},{"id":122,"createTime":18,"updateTime":18,"relativeEntities":157,"slug":18,"properties":158,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":160,"statistic":18},[],{"title":159},{"VI":127},[],{"title":162},{"VI":163},"Nicole M. Warrington",{"id":165,"sortIndex":166,"researcher":18,"roles":167,"affiliations":168,"properties":175,"displayName":177,"givenName":18,"familyName":18},"4097425d-7a8b-4c6f-8a2e-daa2dfcd23d2",3,[119],[169],{"id":122,"sortIndex":19,"affiliation":170,"properties":18},{"id":122,"createTime":18,"updateTime":18,"relativeEntities":171,"slug":18,"properties":172,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":174,"statistic":18},[],{"title":173},{"VI":127},[],{"title":176,"gsAuthor":178},{"VI":177},"Joshua B. Rubin",{"VOID":179},"[\"SHwiOG4AAAAJ\"]","ARTICLE",{"url":114,"publisher":182,"properties":227},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":183,"slug":10,"properties":184,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":187,"manageAffiliations":196,"indexDatabases":212,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":185,"title":186},{"VOID":13},{"EN":15},[188,192],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":189,"label":190,"description":191,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":193,"label":194,"description":195,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[197,202,207],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":198,"slug":18,"properties":199,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":201,"statistic":18},[],{"title":200},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":203,"slug":18,"properties":204,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":206,"statistic":18},[],{"title":205},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":208,"slug":18,"properties":209,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":211,"statistic":18},[],{"title":210},{"EN":53},[],[213,220],{"id":57,"indexDatabase":214,"url":70,"indexYears":18,"academicFieldIds":219,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":215,"label":216,"description":217,"key":66,"publicationTags":218,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":221,"url":85,"indexYears":86,"academicFieldIds":226,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":222,"label":223,"description":224,"key":82,"publicationTags":225,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":228,"volume":230},{"VOID":229},"337-344",{"VOID":231},"32",{"total":19,"publishYear":233,"statisticByYear":234},2011,{},"2011-06-01","ERROR_IN_ANALYZE_CITATION","2026-08-24T17:54:25.077+00:00",[68,90],false,{"id":241,"createTime":242,"updateTime":243,"relativeEntities":244,"slug":245,"properties":246,"entityType":110,"verifyStatus":111,"verifyTime":255,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":256,"fullTextUrl":18,"authors":257,"publicationType":180,"publisherRelationship":299,"citationCount":18,"citationInfo":18,"publishDate":350,"publishYear":351,"citationAnalyzeStatus":352,"lastCitationAnalyze":353,"indexDatabases":354,"openAccess":18,"references":18,"isForceReanalyzing":239},"e4a47602-e0bc-4789-8170-e58e506d8b8c","2023-12-29T12:41:51.524+00:00","2026-08-19T21:48:16.183+00:00",[],"The-molecular-pharmacology-of-CGRP-and-related-peptide-receptor-subtypes",{"title":247,"gsPaper":249,"references":251,"doi":253},{"EN":248},"The molecular pharmacology of CGRP and related peptide receptor subtypes",{"VOID":250},"[]",{"VOID":252},"Amara, 1982, Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products, Nature, 298, 240, 10.1038\u002F298240a0\nRosenfeld, 1982, Calcitonin mRNA polymorphism: peptide switching associated with alternative RNA splicing events, Proc. Natl. Acad. Sci. USA, 79, 1717, 10.1073\u002Fpnas.79.6.1717\nRosenfeld, 1983, Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing, Nature, 304, 129, 10.1038\u002F304129a0\nAmara, 1985, Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide, Science, 229, 1094, 10.1126\u002Fscience.2994212\nVan Rossum, 1997, Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors, Neurosci. Biobehav. Rev., 21, 649, 10.1016\u002FS0149-7634(96)00023-1\nJacques, 2000, Calcitonin gene related peptide (CGRP), amylin and adrenomedullin: anatomical localization and biological functions in the mammalian and human brain., 301, 10.1016\u002FS0924-8196(00)80010-X\nQuirion, 1992, Characterization of CGRP1 and CGRP2 receptor subtypes, Ann. New York Acad. Sci., 657, 88, 10.1111\u002Fj.1749-6632.1992.tb22759.x\nWestermark, 1987, Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone, Am. J. Pathol., 127, 414\nCooper, 1987, Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients, Proc. Natl. Acad. Sci. USA, 84, 8628, 10.1073\u002Fpnas.84.23.8628\nKitamura, 1993, Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma, Biochem. Biophys. Res. Commun., 192, 553, 10.1006\u002Fbbrc.1993.1451\nKitamura, 1993, Cloning and characterization of cDNA encoding a precursor for human adrenomedullin, Biochem. Biophys. Res. Commun., 194, 720, 10.1006\u002Fbbrc.1993.1881\nCooper, 1994, Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease, Endocr. Rev., 15, 163, 10.1210\u002Fedrv-15-2-163\nPoyner, 1995, Pharmacology of receptors for calcitonin gene-related peptide and amylin, Trends Pharmacol. Sci., 16, 424, 10.1016\u002FS0165-6147(00)89093-8\nDoods, 2000, Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist, Br. J. Pharmacol., 129, 420, 10.1038\u002Fsj.bjp.0703110\nMcLatchie, 1998, RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor, Nature, 393, 333, 10.1038\u002F30666\nLuebke, 1996, Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay, Proc. Natl. Acad. Sci. USA, 93, 3455, 10.1073\u002Fpnas.93.8.3455\nDennis, 1989, Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity, J. Pharmacol. Exp. Ther., 251, 718\nDennis, 1990, hCGRP8–37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery, J. Pharmacol. Exp. Ther., 254, 123\nChiba, 1989, Calcitonin gene-related peptide receptor antagonist human CGRP8–37, Am. J. Physiol., 256, E331\nMimeault, 1991, Comparative affinities and antagonistic potenciesof various human calcitonin gene-related peptide fragments on calcitonin gene-related peptide receptors in brain and periphery, J. Pharmacol. Exp. Ther., 258, 1084\nStangl, 1993, Photoaffinity labeling of rat calcitonin gene-related peptide receptors and adenylate cyclase activation: identification of receptor subtypes, Endocrinology, 132, 744, 10.1210\u002Fen.132.2.744\nChin, 1994, Vasodilator responses to calcitonin gene-related peptide (CGRP) and amylin in the rat isolated perfused kidney are mediated via CGRP1 receptors, J. Pharmacol. Exp. Ther., 269, 989\nDumont, 1997, A potent and selective CGRP2 agonist, [Cys(Et)2,7]hCGRPα: comparison in prototypical CGRP1 and CGRP2 in vitro bioassays, Can. J. Physiol. Pharmacol., 75, 671, 10.1139\u002Fcjpp-75-6-671\nMarshall, 1999, CGRP receptor heterogeneity: use of CGRP8–37, 13\nMarshall, 1999, The classification of CGRP, amylin and adrenomedullin receptors: CGRP'98 Consensus view, 255\nQuirion, 1999, Multiple receptors for CGRP and related peptides, 1\nWu, 2000, Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2,7)]hCGRP-preferring receptor, Eur. J. Pharmacol., 400, 313, 10.1016\u002FS0014-2999(00)00407-6\nWisskirchen, 1998, Pharmacological characterization of CGRP receptors mediating relaxation of the rat pulmonary artery and inhibition of twitch responses of the rat vas deferens, Br. J. Pharmacol., 123, 1673, 10.1038\u002Fsj.bjp.0701783\nWisskirchen, 1999, Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by ha CGRP8–37, Br. J. Pharmacol., 128, 283, 10.1038\u002Fsj.bjp.0702764\nPoyner, 1998, Structural determinants for binding to CGRP receptors expressed by human SK-N-MC and Col 29 cells: studies with chimeric and other peptides, Br. J. Pharmacol., 124, 1659, 10.1038\u002Fsj.bjp.0702032\nHowitt, 1997, The selectivity and structural determinants of peptide antagonists at the CGRP receptor of rat, L6 myocytes, Br. J. Pharmacol., 121, 1000, 10.1038\u002Fsj.bjp.0701212\nCox, 1994, Calcitonin gene-related peptide receptors in human gastrointestinal epithelia, Br. J. Pharmacol., 113, 1243, 10.1111\u002Fj.1476-5381.1994.tb17131.x\nRist, 1998, From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor, J. Med. Chem., 41, 117, 10.1021\u002Fjm970533r\nPowell, K.J. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. J. Pharmacol. (in press).\nHenke, 1987, Comparison of binding sites for the calcitonin gene-related peptides I and II in man, Brain Res., 410, 404, 10.1016\u002F0006-8993(87)90348-9\nTomlinson, 1996, Multiple receptors for calcitonin gene-related peptide and amylin on guinea-pig ileum and vas deferens, Br. J. Pharmacol., 117, 1362, 10.1111\u002Fj.1476-5381.1996.tb16737.x\nJansen-Olesen, 1996, Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase, Cephalalgia, 16, 310, 10.1046\u002Fj.1468-2982.1996.1605310.x\nEsfandyari, 2000, A novel receptor for calcitonin gene-related peptide (CGRP) mediates secretion in the rat colon: implications for secretory function in colitis, FASEB J., 14, 1439, 10.1096\u002Ffj.14.10.1439\nLibert, 1989, Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies, Science, 165, 1250\nKapas, 1995, Identification of an orphan receptor gene as a type 1 calcitonin gene-related peptide receptor, Biochem. Biophys. Res. Commun., 217, 832, 10.1006\u002Fbbrc.1995.2847\nHall, 1998, Calcitonin gene-related peptide — a new concept in receptor-ligand specificity?, Trends Pharmacol. Sci., 19, 303, 10.1016\u002FS0165-6147(98)01234-6\nTong, 1999, Discrete expression of a putative CGRP receptor (RDC-1) mRNA in the rat brain and peripheral tissues, 179\nNjuki, 1993, A new calcitonin-receptor-like sequence in rat pulmonary blood vessels, Clin. Sci. (Colch.), 85, 385, 10.1042\u002Fcs0850385\nChang, 1993, Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain, Neuron, 11, 1187, 10.1016\u002F0896-6273(93)90230-O\nFluhmann, 1995, A human orphan calcitonin receptor-like structure, Biochem. Biophys. Res. Commun., 206, 341, 10.1006\u002Fbbrc.1995.1047\nHan, 1997, The interaction of CGRP and adrenomedullin with a receptor expressed in the rat pulmonary vascular endothelium, J. Mol. Endocrinol., 18, 267, 10.1677\u002Fjme.0.0180267\nAiyar, 1996, A cDNA encoding the calcitonin gene-related peptide type 1 receptor, J. Biol. Chem., 271, 11325, 10.1074\u002Fjbc.271.19.11325\nChristopoulos, 1999, Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product, Mol. Pharmacol., 58, 235, 10.1124\u002Fmol.56.1.235\nMuff, 1999, An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3, Endocrinology, 140, 2924, 10.1210\u002Fen.140.6.2924\nTilakaratne, 2000, Amylin receptor phenotypes derived from human calcitonin receptor\u002FRAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment, J. Pharmacol. Exp. Ther., 294, 61\nBuhlmann, 1999, A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1, Endocrinology, 140, 2883, 10.1210\u002Fen.140.6.2883\nDrake, 1999, Desensitization of CGRP and adrenomedullin receptors in SK-N-MC cells: implications for the RAMP hypothesis, Endocrinology, 140, 533, 10.1210\u002Fen.140.1.533\nFrayon, 2000, Dexamethasone increases RAMP1 and CRLR mRNA expressions in human vascular smooth muscle cells, Biochem. Biophys. Res. Commun., 270, 1063, 10.1006\u002Fbbrc.2000.2552\nNagae, 2000, Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin\u002FCGRP receptor: cloning and upregulation in obstructive nephropathy, Biochem. Biophys. Res. Commun., 270, 89, 10.1006\u002Fbbrc.2000.2390\nRosenblatt, M.I. et al. (1999) The CGRP receptor component protein: A novel signal transduction protein. In The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin (Poyner, D. et al., eds), pp. 67–76, Landes Bioscience.\nRosenblatt, 2000, Characterization and localization of the rabbit ocular calcitonin gene-related peptide (CGRP)-receptor component protein (RCP), Invest. Ophthalmol. Vis. Sci., 41, 1159\nEvans, 2000, CGRP-RCP: a novel protein required for signal transduction at CGRP and adrenomedullin receptors, J. Biol. Chem., 275, 31438, 10.1074\u002Fjbc.M005604200\nChantry, 1991, Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes, Biochem. J., 277, 139, 10.1042\u002Fbj2770139\nAiyar, 1995, Differential calcitonin gene-related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: potential models for studying CGRP\u002Famylin receptor subtypes, J. Neurochem., 65, 1131, 10.1046\u002Fj.1471-4159.1995.65031131.x\nBell, 1995, Activity of amylin at CGRP1-preferring receptors coupled to positive contractile response in rat ventricular cardiomyocytes, Regul. Pept., 60, 125, 10.1016\u002F0167-0115(95)00120-4\nHall, 1999, Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch in vivo, Br. J. Pharmacol., 126, 280, 10.1038\u002Fsj.bjp.0702272\nD'Santos, 1992, Stimulation of adenylate cyclase by amylin in CHO-K1 cells, Mol. Pharmacol., 41, 894\nBeaumont, 1995, Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved, Br. J. Pharmacol., 115, 713, 10.1111\u002Fj.1476-5381.1995.tb14991.x\nBeaumont, 1995, Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists, Can. J. Physiol. Pharmacol., 73, 1025, 10.1139\u002Fy95-144\nVan Rossum, 1994, Autoradiographic distribution and receptor binding profile of [125I]Bolton Hunter-rat amylin binding sites in the rat brain, J. Pharmacol. Exp. Ther., 270, 779\nBeaumont, 1993, High affinity amylin binding sites in rat brain, Mol. Pharmacol., 44, 493\nSexton, 1994, In vitro autoradiographic localization of amylin binding sites in rat brain, Neuroscience, 62, 553, 10.1016\u002F0306-4522(94)90388-3\nVeale, 1994, The presence of islet amyloid polypeptide\u002Fcalcitonin gene-related peptide\u002Fsalmon calcitonin binding sites in the rat nucleus accumbens, Eur. J. Pharmacol., 262, 133, 10.1016\u002F0014-2999(94)90036-1\nSkofitsch, 1992, Calcitonin and calcitonin gene-related peptide receptor binding sites in the rat central nervous system, Ann. New York Acad. Sci., 657, 420, 10.1111\u002Fj.1749-6632.1992.tb22788.x\nChen, 1997, Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors, Mol. Pharmacol., 52, 1164, 10.1124\u002Fmol.52.6.1164\nZumpe, 2000, Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product, Biochem. Biophys. Res. Commun., 267, 368, 10.1006\u002Fbbrc.1999.1943\nEntzeroth, 1995, Adrenomedullin mediates vasodilation via CGRP1 receptors, Life Sci., 58, L19\nCoppock, 1996, A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors, Biochem. J., 318, 241, 10.1042\u002Fbj3180241\nMazzocchi, 1996, Adrenomedullin and calcitonin gene-related peptide inhibit aldosterone secretion in rats, acting via a common receptor, Life Sci., 58, 839, 10.1016\u002F0024-3205(96)00017-3\nPinto, 1996, Effects of adrenomedullin and calcitonin gene-related peptide on airway and pulmonary vascular smooth muscle in guinea-pigs, Br. J. Pharmacol., 119, 1477, 10.1111\u002Fj.1476-5381.1996.tb16061.x\nGardiner, 1995, Regional haemodynamic effects of human and rat adrenomedullin in conscious rats, Br. J. Pharmacol., 114, 584, 10.1111\u002Fj.1476-5381.1995.tb17179.x\nKapas, 1998, Local production and action of adrenomedullin in the rat adrenal zona glomerulosa, J. Endocrinol., 156, 477, 10.1677\u002Fjoe.0.1560477\nElhawary, 1995, Effects of calcitonin gene-related peptide receptor antagonists on renal actions of adrenomedullin, Br. J. Pharmacol., 115, 1133, 10.1111\u002Fj.1476-5381.1995.tb15015.x\nVan Rossum, 1995, Comparative affinities of human adrenomedullin for 125I-labelled human a calcitonin gene related peptide ([125I]hCGRPa) and 125I-labelled Bolton-Hunter rat amylin ([125I]BHrAMY) specific binding sites in the rat brain, Can. J. Physiol. Pharmacol., 73, 1084, 10.1139\u002Fy95-155\nMoreno, 1999, Functional calcitonin gene-related peptide type 1 and adrenomedullin receptors in human trigeminal ganglia, brain vessels, and cerebromicrovascular or astroglial cells in culture, J. Cereb. Blood Flow Metab., 19, 1270, 10.1097\u002F00004647-199911000-00012\nPoyner, 1999, Characterization of receptors for calcitonin gene-related peptide and adrenomedullin on the guinea-pig vas deferens, Br. J. Pharmacol., 126, 1276, 10.1038\u002Fsj.bjp.0702437\nChampion, 1997, Proadrenomedullin NH2-terminal 20 peptide has direct vasodilator activity in the cat, Am. J. Physiol., 272, R1047\nJuaneda, 2000, Comparative pharmacological profile of [125I]-hADM1–52 and [125I]-hADM13–52 receptor binding sites in the central nervous system and peripheral tissues: evidence for adrenomedullin receptor sub-types, Soc. Neurosci. Abstr., 26, 382\nKapas, 1995, Cloning and expression of cDNA encoding a rat adrenomedullin receptor, J. Biol. Chem., 270, 25344, 10.1074\u002Fjbc.270.43.25344\nHanze, 1997, Molecular cloning of a novel human receptor gene with homology to the rat adrenomedullin receptor and high expression in heart and immune system, Biochem. Biophys. Res. Commun., 240, 183, 10.1006\u002Fbbrc.1997.7631\nOwji, 1995, An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat, Endocrinology, 136, 2127, 10.1210\u002Fen.136.5.2127\nKennedy, 1998, Expression of the rat adrenomedullin receptor or a putative human adrenomedullin receptor does not correlate with adrenomedullin binding or functional response, Biochem. Biophys. Res. Commun., 244, 832, 10.1006\u002Fbbrc.1998.8349\nHinson, 2000, Adrenomedullin, a multifunctional regulatory peptide, Endocr. Rev., 21, 138, 10.1210\u002Fer.21.2.138",{"VOID":254},"10.1016\u002Fs0165-6147(00)01555-8","2024-09-05T06:35:03.198+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165614700015558",[258,273,286],{"id":259,"sortIndex":19,"researcher":18,"roles":260,"affiliations":261,"properties":270,"displayName":272,"givenName":18,"familyName":18},"4c4a5413-2adc-46d2-9e35-368379fd8542",[119],[262],{"id":263,"sortIndex":19,"affiliation":264,"properties":18},"f888dcf7-9785-4a5a-a5b9-9c32269fb865",{"id":263,"createTime":18,"updateTime":18,"relativeEntities":265,"slug":18,"properties":266,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":269,"statistic":18},[],{"title":267},{"VI":268},"Department of Psychiatry, Douglas Hospital Research Centre, Faculty of Medicine, McGill University, Montreal, Que., Canada H4H 1R3.",[],{"title":271},{"VI":272},"Christian Juaneda",{"id":274,"sortIndex":136,"researcher":18,"roles":275,"affiliations":276,"properties":283,"displayName":285,"givenName":18,"familyName":18},"fb27a4c6-d7b6-4770-af37-9161be6a6b49",[119],[277],{"id":263,"sortIndex":19,"affiliation":278,"properties":18},{"id":263,"createTime":18,"updateTime":18,"relativeEntities":279,"slug":18,"properties":280,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":282,"statistic":18},[],{"title":281},{"VI":268},[],{"title":284},{"VI":285},"Yvan Dumont",{"id":287,"sortIndex":152,"researcher":18,"roles":288,"affiliations":289,"properties":296,"displayName":298,"givenName":18,"familyName":18},"4cac4a56-bb78-4a6d-98f0-0d7201b68492",[119],[290],{"id":263,"sortIndex":19,"affiliation":291,"properties":18},{"id":263,"createTime":18,"updateTime":18,"relativeEntities":292,"slug":18,"properties":293,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":295,"statistic":18},[],{"title":294},{"VI":268},[],{"title":297},{"VI":298},"Rémi Quirion",{"url":256,"publisher":300,"properties":345},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":301,"slug":10,"properties":302,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":305,"manageAffiliations":314,"indexDatabases":330,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":303,"title":304},{"VOID":13},{"EN":15},[306,310],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":307,"label":308,"description":309,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":311,"label":312,"description":313,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[315,320,325],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":316,"slug":18,"properties":317,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":319,"statistic":18},[],{"title":318},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":321,"slug":18,"properties":322,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":324,"statistic":18},[],{"title":323},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":326,"slug":18,"properties":327,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":329,"statistic":18},[],{"title":328},{"EN":53},[],[331,338],{"id":57,"indexDatabase":332,"url":70,"indexYears":18,"academicFieldIds":337,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":333,"label":334,"description":335,"key":66,"publicationTags":336,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":339,"url":85,"indexYears":86,"academicFieldIds":344,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":340,"label":341,"description":342,"key":82,"publicationTags":343,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":346,"volume":348},{"VOID":347},"432-438",{"VOID":349},"21","2000-11-01",2000,"ERROR_IN_GET_PLATFORM_ID","2026-08-19T21:48:16.182+00:00",[68,90],{"id":356,"createTime":357,"updateTime":358,"relativeEntities":359,"slug":360,"properties":361,"entityType":110,"verifyStatus":111,"verifyTime":374,"verifyNote":113,"languages":375,"translateLanguages":18,"viewCount":19,"primaryUrl":377,"fullTextUrl":18,"authors":378,"publicationType":180,"publisherRelationship":432,"citationCount":19,"citationInfo":485,"publishDate":488,"publishYear":486,"citationAnalyzeStatus":236,"lastCitationAnalyze":489,"indexDatabases":490,"openAccess":18,"references":491,"isForceReanalyzing":239},"fc574531-2f92-4601-80eb-06e76cf9abfa","2024-09-21T18:37:11.250+00:00","2026-08-18T07:39:24.854+00:00",[],"Neuroactive-steroids-potential-therapeutic-use-in-neurological-and-psychiatric-disorders",{"openalex":362,"mag":364,"title":366,"gsPaper":368,"pm":370,"doi":372},{"VOID":363},"W2048706813",{"VOID":365},"2048706813",{"EN":367},"Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders",{"VOID":369},"[\"13215644315762560548\"]",{"VOID":371},"10203866",{"VOID":373},"10.1016\u002Fs0165-6147(99)01318-8","2024-09-21T18:37:11.249+00:00",[376],"EN","https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0165614799013188",[379,396,415],{"id":380,"sortIndex":19,"researcher":18,"roles":381,"affiliations":382,"properties":391,"displayName":393,"givenName":18,"familyName":18},"d530f9ad-33a6-4f38-b843-cd4caffab33d",[],[383],{"id":384,"sortIndex":19,"affiliation":385,"properties":18},"6aa481b9-dbc5-44e3-831b-87e777d4ddd1",{"id":384,"createTime":18,"updateTime":18,"relativeEntities":386,"slug":18,"properties":387,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":390,"statistic":18},[],{"title":388},{"EN":389},"Drug Development Group, Behavioral Neuroscience Branch, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA",[],{"title":392,"openalex":394},{"EN":393},"Maciej Gąsior",{"VOID":395},"A5021753249",{"id":397,"sortIndex":136,"researcher":18,"roles":398,"affiliations":399,"properties":408,"displayName":410,"givenName":18,"familyName":18},"02759a70-925c-4aba-9744-9b38f04d23c6",[],[400],{"id":401,"sortIndex":19,"affiliation":402,"properties":18},"68bed947-30df-4733-8c9b-10b6567b2a88",{"id":401,"createTime":18,"updateTime":18,"relativeEntities":403,"slug":18,"properties":404,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":407,"statistic":18},[],{"title":405},{"EN":406},"Pharmacology CoCensys Inc., Irvine, CA 92618, USA.",[],{"title":409,"gsAuthor":411,"openalex":413},{"EN":410},"Richard B. Carter",{"VOID":412},"[\"KF4sVMUAAAAJ\"]",{"VOID":414},"A5041406777",{"id":416,"sortIndex":152,"researcher":18,"roles":417,"affiliations":418,"properties":425,"displayName":429,"givenName":18,"familyName":18},"0b421e83-b9ae-4878-8111-a21b17b02abe",[],[419],{"id":384,"sortIndex":19,"affiliation":420,"properties":18},{"id":384,"createTime":18,"updateTime":18,"relativeEntities":421,"slug":18,"properties":422,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":424,"statistic":18},[],{"title":423},{"EN":389},[],{"orcid":426,"title":428,"openalex":430},{"VOID":427},"https:\u002F\u002Forcid.org\u002F0000-0002-9048-148X",{"EN":429},"Jeffrey M. Witkin",{"VOID":431},"A5090899159",{"url":18,"publisher":433,"properties":478},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":434,"slug":10,"properties":435,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":438,"manageAffiliations":447,"indexDatabases":463,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":436,"title":437},{"VOID":13},{"EN":15},[439,443],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":440,"label":441,"description":442,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":444,"label":445,"description":446,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[448,453,458],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":449,"slug":18,"properties":450,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":452,"statistic":18},[],{"title":451},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":454,"slug":18,"properties":455,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":457,"statistic":18},[],{"title":456},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":459,"slug":18,"properties":460,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":462,"statistic":18},[],{"title":461},{"EN":53},[],[464,471],{"id":57,"indexDatabase":465,"url":70,"indexYears":18,"academicFieldIds":470,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":466,"label":467,"description":468,"key":66,"publicationTags":469,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":472,"url":85,"indexYears":86,"academicFieldIds":477,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":473,"label":474,"description":475,"key":82,"publicationTags":476,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"issue":479,"pages":481,"volume":483},{"VOID":480},"3",{"VOID":482},"107-112",{"VOID":484},"20",{"total":19,"publishYear":486,"statisticByYear":487},1999,{},"1999-03-01","2026-08-18T07:39:24.853+00:00",[68,90],[492,495,499,503,506,510,514,517,520,523,527,531,535,538,542,546,550,554,557,560,564,568,571,575,579,582,585,589,593,597,600,603,607,611,614,618,622,625,628,631,634,638,642,645,648,651,654,657,661,665,668,672,676,680,684,688,692,696,700,704],{"id":18,"text":493,"url":18,"identifiers":494},"Gee, 1995, Crit. Rev. Neurobiol., 9, 207",{},{"id":18,"text":496,"url":18,"identifiers":497},"Lambert, 1995, Trends Pharmacol. Sci., 16, 295, 10.1016\u002FS0165-6147(00)89058-6",{"doi":498},"10.1016\u002FS0165-6147(00)89058-6",{"id":18,"text":500,"url":18,"identifiers":501},"Rupprecht, 1997, J. Psychiatr. Res., 31, 297, 10.1016\u002FS0022-3956(96)00060-X",{"doi":502},"10.1016\u002FS0022-3956(96)00060-X",{"id":18,"text":504,"url":18,"identifiers":505},"McNamara, 1993, 27",{},{"id":18,"text":507,"url":18,"identifiers":508},"Shinnar, 1996, Epilepsia, 37, 701, 10.1111\u002Fj.1528-1157.1996.tb00639.x",{"doi":509},"10.1111\u002Fj.1528-1157.1996.tb00639.x",{"id":18,"text":511,"url":18,"identifiers":512},"Belelli, 1990, Neurosci. Biobehav. Rev., 14, 315, 10.1016\u002FS0149-7634(05)80041-7",{"doi":513},"10.1016\u002FS0149-7634(05)80041-7",{"id":18,"text":515,"url":18,"identifiers":516},"Kokate, 1994, J. Pharmacol. Exp. Ther., 270, 1223",{},{"id":18,"text":518,"url":18,"identifiers":519},"Carter, 1997, J. Pharmacol. Exp. Ther., 280, 1284",{},{"id":18,"text":521,"url":18,"identifiers":522},"Gasior, 1997, J. Pharmacol. Exp. Ther., 282, 543",{},{"id":18,"text":524,"url":18,"identifiers":525},"Kokate, 1996, Neuropharmacology, 35, 1049, 10.1016\u002FS0028-3908(96)00021-4",{"doi":526},"10.1016\u002FS0028-3908(96)00021-4",{"id":18,"text":528,"url":18,"identifiers":529},"Gasior, 1998, Drug Dev. Res., 44, 21, 10.1002\u002F(SICI)1098-2299(199805)44:1\u003C21::AID-DDR4>3.0.CO;2-R",{"doi":530},"10.1002\u002F(SICI)1098-2299(199805)44:1\u003C21::AID-DDR4>3.0.CO;2-R",{"id":18,"text":532,"url":18,"identifiers":533},"Monaghan, E. P. et al. (1997) Epilepsia 38 (Suppl. 8), 179",{"doi":534},"10.1111\u002Fj.1528-1157.1997.tb01486.x",{"id":18,"text":536,"url":18,"identifiers":537},"Shields, 1997, Ann. Neurol., 42, 503",{},{"id":18,"text":539,"url":18,"identifiers":540},"Wieland, 1991, Brain Res., 565, 263, 10.1016\u002F0006-8993(91)91658-N",{"doi":541},"10.1016\u002F0006-8993(91)91658-N",{"id":18,"text":543,"url":18,"identifiers":544},"Crawley, 1986, Brain Res., 398, 382, 10.1016\u002F0006-8993(86)91500-3",{"doi":545},"10.1016\u002F0006-8993(86)91500-3",{"id":18,"text":547,"url":18,"identifiers":548},"Wieland, 1995, Psychopharmacology, 118, 65, 10.1007\u002FBF02245251",{"doi":549},"10.1007\u002FBF02245251",{"id":18,"text":551,"url":18,"identifiers":552},"Brot, 1997, Eur. J. Pharmacol., 325, 1, 10.1016\u002FS0014-2999(97)00096-4",{"doi":553},"10.1016\u002FS0014-2999(97)00096-4",{"id":18,"text":555,"url":18,"identifiers":556},"Edgar, 1997, J. Pharmacol. Exp. Ther., 282, 420",{},{"id":18,"text":558,"url":18,"identifiers":559},"Abrol, 1997, Soc. Neurosci. Abstr., 23, 960",{},{"id":18,"text":561,"url":18,"identifiers":562},"Rodgers, 1998, Pharmacol. Biochem. Behav., 59, 221, 10.1016\u002FS0091-3057(97)00339-0",{"doi":563},"10.1016\u002FS0091-3057(97)00339-0",{"id":18,"text":565,"url":18,"identifiers":566},"Bitran, 1991, Brain Res., 561, 157, 10.1016\u002F0006-8993(91)90761-J",{"doi":567},"10.1016\u002F0006-8993(91)90761-J",{"id":18,"text":569,"url":18,"identifiers":570},"Vivian, 1997, J. Pharmacol. Exp. Ther., 282, 318",{},{"id":18,"text":572,"url":18,"identifiers":573},"Zimmerberg, 1994, Pharmacol. Biochem. Behav., 47, 735, 10.1016\u002F0091-3057(94)90181-3",{"doi":574},"10.1016\u002F0091-3057(94)90181-3",{"id":18,"text":576,"url":18,"identifiers":577},"Picazo, 1995, Brain Res., 680, 135, 10.1016\u002F0006-8993(95)00254-N",{"doi":578},"10.1016\u002F0006-8993(95)00254-N",{"id":18,"text":580,"url":18,"identifiers":581},"Beekman, 1998, J. Pharmacol. Exp. Ther., 284, 868",{},{"id":18,"text":583,"url":18,"identifiers":584},"Lancel, 1997, J. Pharmacol. Exp. Ther., 282, 1213",{},{"id":18,"text":586,"url":18,"identifiers":587},"Barbaccia, 1997, Br. J. Pharmacol., 120, 1582, 10.1038\u002Fsj.bjp.0701046",{"doi":588},"10.1038\u002Fsj.bjp.0701046",{"id":18,"text":590,"url":18,"identifiers":591},"Mendelson, 1987, Psychopharmacology, 93, 226, 10.1007\u002FBF00179939",{"doi":592},"10.1007\u002FBF00179939",{"id":18,"text":594,"url":18,"identifiers":595},"Limmroth, 1996, Br. J. Pharmacol., 117, 99, 10.1111\u002Fj.1476-5381.1996.tb15160.x",{"doi":596},"10.1111\u002Fj.1476-5381.1996.tb15160.x",{"id":18,"text":598,"url":18,"identifiers":599},"Moskowitz, 1998, Am. Assoc. Stud. Headache Syllabus",{},{"id":18,"text":601,"url":18,"identifiers":602},"Data, 1998, Am. Assoc. Stud. Headache Syllabus",{},{"id":18,"text":604,"url":18,"identifiers":605},"Devaud, 1995, Alcohol Clin. Exp. Res., 19, 350, 10.1111\u002Fj.1530-0277.1995.tb01514.x",{"doi":606},"10.1111\u002Fj.1530-0277.1995.tb01514.x",{"id":18,"text":608,"url":18,"identifiers":609},"Finn, 1995, Alcohol Clin. Exp. Res., 19, 410, 10.1111\u002Fj.1530-0277.1995.tb01523.x",{"doi":610},"10.1111\u002Fj.1530-0277.1995.tb01523.x",{"id":18,"text":612,"url":18,"identifiers":613},"Devaud, 1996, J. Pharmacol. Exp. Ther., 278, 510",{},{"id":18,"text":615,"url":18,"identifiers":616},"Reddy, 1997, Eur. J. Pharmacol., 337, 19, 10.1016\u002FS0014-2999(97)01294-6",{"doi":617},"10.1016\u002FS0014-2999(97)01294-6",{"id":18,"text":619,"url":18,"identifiers":620},"Budziszewska, 1996, Eur. Neuropsychopharmacol., 6, 135, 10.1016\u002F0924-977X(96)00003-X",{"doi":621},"10.1016\u002F0924-977X(96)00003-X",{"id":18,"text":623,"url":18,"identifiers":624},"Reddy, 1997, Methods Find. Exp. Clin. Pharmacol., 19, 395",{},{"id":18,"text":626,"url":18,"identifiers":627},"Rogawski, 1990, Pharmacol. Rev., 42, 223",{},{"id":18,"text":629,"url":18,"identifiers":630},"Dhuna, 1991, Neurotoxicology, 12, 621",{},{"id":18,"text":632,"url":18,"identifiers":633},"Rogawski, 1996, 193",{},{"id":18,"text":635,"url":18,"identifiers":636},"Frye, 1995, Brain Res., 696, 113, 10.1016\u002F0006-8993(95)00793-P",{"doi":637},"10.1016\u002F0006-8993(95)00793-P",{"id":18,"text":639,"url":18,"identifiers":640},"Schumacher, 1996, Dev. Neurosci., 18, 6, 10.1159\u002F000111391",{"doi":641},"10.1159\u002F000111391",{"id":18,"text":643,"url":18,"identifiers":644},"Monaghan, 1997, Epilepsia, 38, 1026, 10.1111\u002Fj.1528-1157.1997.tb01486.x",{"doi":534},{"id":18,"text":646,"url":18,"identifiers":647},"Lader, 1995, 135",{},{"id":18,"text":649,"url":18,"identifiers":650},"Baldessarini, R. J. (1996) in Goodman and Gilman's The Pharmacological Basis of Therapeutics (9th edn) (Hardman, J. G. et al., eds), pp. 399–430, McGraw-Hill",{},{"id":18,"text":652,"url":18,"identifiers":653},"Miczek, K. A. et al. (1997) in Recent Developments in Alcoholism (Vol. 13) Alcoholism and Violence (Galanter, M., ed.), pp. 139–171, Plenum Press",{},{"id":18,"text":655,"url":18,"identifiers":656},"Britton, 1991, J. Pharmacol. Exp. Ther., 258, 124",{},{"id":18,"text":658,"url":18,"identifiers":659},"Wieland, 1997, Psychopharmacology, 134, 46, 10.1007\u002Fs002130050424",{"doi":660},"10.1007\u002Fs002130050424",{"id":18,"text":662,"url":18,"identifiers":663},"Lancel, 1996, Am. J. Physiol., 271, E763, 10.1152\u002Fajpcell.1996.271.3.C763",{"doi":664},"10.1152\u002Fajpcell.1996.271.3.C763",{"id":18,"text":666,"url":18,"identifiers":667},"Friess, 1997, Am. J. Physiol., 272, E885",{},{"id":18,"text":669,"url":18,"identifiers":670},"Hill-Venning, 1996, Neuropharmacology, 35, 1209, 10.1016\u002FS0028-3908(96)00069-X",{"doi":671},"10.1016\u002FS0028-3908(96)00069-X",{"id":18,"text":673,"url":18,"identifiers":674},"Sear, 1998, Eur. J. Anaesthesiol., 15, 129, 10.1097\u002F00003643-199803000-00001",{"doi":675},"10.1097\u002F00003643-199803000-00001",{"id":18,"text":677,"url":18,"identifiers":678},"Bradley, 1968, Br. Med. J., 3, 531, 10.1136\u002Fbmj.3.5617.531",{"doi":679},"10.1136\u002Fbmj.3.5617.531",{"id":18,"text":681,"url":18,"identifiers":682},"Lundberg, 1968, Acta Neurol. Scand., 45, 309, 10.1111\u002Fj.1600-0404.1969.tb01243.x",{"doi":683},"10.1111\u002Fj.1600-0404.1969.tb01243.x",{"id":18,"text":685,"url":18,"identifiers":686},"Chen, 1994, Headache, 34, 107, 10.1111\u002Fj.1526-4610.1994.hed3402107.x",{"doi":687},"10.1111\u002Fj.1526-4610.1994.hed3402107.x",{"id":18,"text":689,"url":18,"identifiers":690},"Emmett-Oglesby, 1990, Psychopharmacology, 101, 292, 10.1007\u002FBF02244046",{"doi":691},"10.1007\u002FBF02244046",{"id":18,"text":693,"url":18,"identifiers":694},"Marshall, 1997, Pharmacol. Biochem. Behav., 58, 1, 10.1016\u002FS0091-3057(96)00132-3",{"doi":695},"10.1016\u002FS0091-3057(96)00132-3",{"id":18,"text":697,"url":18,"identifiers":698},"Vanover, 1999, Psychopharmacology, 141, 77, 10.1007\u002Fs002130050809",{"doi":699},"10.1007\u002Fs002130050809",{"id":18,"text":701,"url":18,"identifiers":702},"Finn, 1997, Pharmacol. Biochem. Behav., 56, 261, 10.1016\u002FS0091-3057(96)00218-3",{"doi":703},"10.1016\u002FS0091-3057(96)00218-3",{"id":18,"text":705,"url":18,"identifiers":706},"Winger, G. et al. (1996) Behav. Pharmacol. 7 (Suppl. 1), 121",{"doi":707},"10.1097\u002F00008877-199605001-00276",{"id":709,"createTime":710,"updateTime":711,"relativeEntities":712,"slug":713,"properties":714,"entityType":110,"verifyStatus":111,"verifyTime":722,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":723,"fullTextUrl":18,"authors":724,"publicationType":180,"publisherRelationship":857,"citationCount":18,"citationInfo":18,"publishDate":907,"publishYear":233,"citationAnalyzeStatus":352,"lastCitationAnalyze":908,"indexDatabases":909,"openAccess":18,"references":18,"isForceReanalyzing":239},"3aa9df89-3735-449f-8171-40bf74215801","2023-12-29T10:45:07.576+00:00","2026-08-17T22:00:05.102+00:00",[],"Mast-cells-squeeze-the-heart-and-stretch-the-gird-Their-role-in-atherosclerosis-and-obesity",{"title":715,"gsPaper":717,"references":718,"doi":720},{"EN":716},"Mast cells squeeze the heart and stretch the gird: Their role in atherosclerosis and obesity",{"VOID":250},{"VOID":719},"Beaven, 2009, Our perception of the mast cell from Paul Ehrlich to now, Eur. J. Immunol., 39, 11, 10.1002\u002Feji.200838899\nRottem, 2005, Mast cells and autoimmunity, Autoimmun. Rev., 4, 21, 10.1016\u002Fj.autrev.2004.05.001\nGalli, 2008, The development of allergic inflammation, Nature, 454, 445, 10.1038\u002Fnature07204\nTheoharides, 2010, Mast cells and inflammation, Biochim. Biophys. Acta\nAbraham, 2010, Mast cell-orchestrated immunity to pathogens, Nat. Rev. Immunol., 10, 440, 10.1038\u002Fnri2782\nGong, 2010, The antigen presentation function of bone marrow-derived mast cells is spatiotemporally restricted to a subset expressing high levels of cell surface FcepsilonRI and MHC II, BMC Immunol., 11, 34, 10.1186\u002F1471-2172-11-34\nCrivellato, 2010, Mast cells and basophils: a potential link in promoting angiogenesis during allergic inflammation, Int. Arch. Allergy Immunol., 151, 89, 10.1159\u002F000235998\nKitamura, 2005, Mast cell-committed progenitors, Proc. Natl. Acad. Sci. U.S.A., 102, 11129, 10.1073\u002Fpnas.0505073102\nPoglio, 2010, Adipose tissue as a dedicated reservoir of functional mast cell progenitors, Stem Cells, 28, 2065, 10.1002\u002Fstem.523\nGurish, 2006, Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell, J. Allergy Clin. Immunol., 117, 1285, 10.1016\u002Fj.jaci.2006.04.017\nDvorak, 1986, Mast-cell degranulation in human hearts, N. Engl. J. Med., 315, 969, 10.1056\u002FNEJM198610093151515\nPatella, 1995, Human heart mast cells: a definitive case of mast cell heterogeneity, Int. Arch. Allergy Immunol., 106, 386, 10.1159\u002F000236871\nKovanen, 1995, Role of mast cells in atherosclerosis, Chem. Immunol., 62, 132, 10.1159\u002F000319300\nZhang, J. and Shi, G.P. Mast cells and metabolic syndrome. Biochim. Biophys. Acta, 2010 Dec 23. [Epub ahead of print], doi:10.1016\u002Fj.bbadis.2010.12.012\nRoss, 1999, Atherosclerosis-an inflammatory disease, N. Engl. J. Med., 340, 115, 10.1056\u002FNEJM199901143400207\nHansson, 2011, The immune system in atherosclerosis, Nat. Immunol., 12, 204, 10.1038\u002Fni.2001\nLibby, 2002, Inflammation and atherosclerosis, Circulation, 105, 1135, 10.1161\u002Fhc0902.104353\nSuzuki, 2003, Relation of C-reactive protein and interleukin-6 to culprit coronary artery plaque size in patients with acute myocardial infarction, Am. J. Cardiol., 91, 331, 10.1016\u002FS0002-9149(02)03162-4\nDeliargyris, 2000, Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure, Am. J. Cardiol., 86, 913, 10.1016\u002FS0002-9149(00)01121-8\nPai, 2004, Inflammatory markers and the risk of coronary heart disease in men and women, N. Engl. J. Med., 351, 2599, 10.1056\u002FNEJMoa040967\nKandere-Grzybowska, 2006, Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin, Br. J. Pharmacol., 148, 208, 10.1038\u002Fsj.bjp.0706695\nForman, 1985, Increased adventitial mast cells in a patient with coronary spasm, N. Engl. J. Med., 313, 1138, 10.1056\u002FNEJM198510313131807\nConstantinides, 1995, Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction, Circulation, 92, 1083, 10.1161\u002F01.CIR.92.5.1083\nKaartinen, 1996, Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-a, Circulation, 94, 2787, 10.1161\u002F01.CIR.94.11.2787\nLaine, 1999, Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery, Circulation, 99, 361, 10.1161\u002F01.CIR.99.3.361\nKounis, 2007, Coronary stents, hypersensitivity reactions and the Kounis syndrome, J. Invasive Cardiol., 20, 314, 10.1111\u002Fj.1540-8183.2007.00283.x\nKrantz, 2000, Effects of mental stress in patients with coronary artery disease: evidence and clinical implications, JAMA, 283, 1800, 10.1001\u002Fjama.283.14.1800\nCao, 2005, Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor, J. Immunol., 174, 7665, 10.4049\u002Fjimmunol.174.12.7665\nHuang, 2009, Urocortin induces IL-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-{kappa}B activation, J. Mol. Endocrinol., 42, 397, 10.1677\u002FJME-08-0120\nKelley, 2006, Mast cell activation by lipoproteins, Methods Mol. Biol., 315, 341\nFrangogiannis, 2002, The inflammatory response in myocardial infarction, Cardiovasc. Res., 53, 31, 10.1016\u002FS0008-6363(01)00434-5\nTheoharides, 2007, Differential release of mast cell mediators and the pathogenesis of inflammation, Immunol. Rev., 217, 65, 10.1111\u002Fj.1600-065X.2007.00519.x\nLerman, 1995, Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans, Circulation, 92, 2426, 10.1161\u002F01.CIR.92.9.2426\nReriani, 2010, Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis, Circulation, 122, 958, 10.1161\u002FCIRCULATIONAHA.110.967406\nMurray, 2004, Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats, Am. J. Physiol. Heart Circ. Physiol., 287, H2295, 10.1152\u002Fajpheart.00048.2004\nMaurer, 2004, Mast cells promote homeostasis by limiting endothelin-1-induced toxicity, Nature, 432, 512, 10.1038\u002Fnature03085\nMasini, 2002, Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo, Br. J. Pharmacol., 136, 905, 10.1038\u002Fsj.bjp.0704774\nSwindle, 2007, The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes, Immunol. Rev., 217, 186, 10.1111\u002Fj.1600-065X.2007.00513.x\nTagen, 2009, Mitochondrial uncoupling protein 2 (UCP2) inhibits mast cell activation and reduces histamine content, J. Immunol., 183, 6313, 10.4049\u002Fjimmunol.0803422\nChiao, 1996, The role of substance P in myocardial dysfunction during ischemia and reperfusion, Naunyn Schmiedebergs Arch. Pharmacol., 353, 400, 10.1007\u002FBF00261436\nMorrey, 2010, Interaction between sensory C-fibers and cardiac mast cells in ischemia\u002Freperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction, J. Pharmacol. Exp. Ther., 335, 76, 10.1124\u002Fjpet.110.172262\nBot, 2010, The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis, Circ. Res., 106, 89, 10.1161\u002FCIRCRESAHA.109.204875\nTheoharides, 2010, IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin, Proc. Natl. Acad. Sci. U.S.A., 107, 4448, 10.1073\u002Fpnas.1000803107\nQuirion, 1980, Selective blockade of neurotensin-induced coronary vessel constriction in perfused rat hearts by a neurotensin analogue, Eur. J. Pharmacol., 61, 309, 10.1016\u002F0014-2999(80)90133-8\nDonelan, 2006, Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process, Proc. Natl. Acad. Sci. U.S.A., 103, 7759, 10.1073\u002Fpnas.0602210103\nPang, 1998, A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process, J. Pharm. Exp. Ther., 287, 307\nZelkha, 2010, Periodontal innate immune mechanisms relevant to atherosclerosis and obesity, Periodontology 2000, 54, 207, 10.1111\u002Fj.1600-0757.2010.00358.x\nMullick, 2008, Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events, J. Exp. Med., 205, 373, 10.1084\u002Fjem.20071096\nKulka, 2004, Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3, J. Allergy Clin. Immunol., 114, 174, 10.1016\u002Fj.jaci.2004.03.049\nZhang, 2011, Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis, J. Allergy Clin. Immunol., 127, 1522, 10.1016\u002Fj.jaci.2011.02.005\nGrimbaldeston, 2005, Mast cell-deficient W-sash c-kit mutant Kit W-sh\u002FW-sh mice as a model for investigating mast cell biology in vivo, Am. J. Pathol., 167, 835, 10.1016\u002FS0002-9440(10)62055-X\nHuang, 2003, Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in apolipoprotein E knockout mice, Cardiovasc. Res., 59, 241, 10.1016\u002FS0008-6363(03)00340-7\nBhattacharya, 2007, Mast cell deficient W\u002FWv mice have lower serum IL-6 and less cardiac tissue necrosis than their normal littermates following myocardial ischemia-reperfusion, Int. J. Immunopathol. Pharmacol., 20, 69, 10.1177\u002F039463200702000108\nGordon, 1991, J. Exp. Med., 174, 103, 10.1084\u002Fjem.174.1.103\nFrangogiannis, 1998, Resident cardiac mast cells degranulate and release preformed TNF-a, initiating the cytokine cascade in experimental canine myocardial ischemia\u002Freperfusion, Circulation, 98, 699, 10.1161\u002F01.CIR.98.7.699\nSun, 2007, Mast cells promote atherosclerosis by releasing proinflammatory cytokines, Nat. Med., 13, 719, 10.1038\u002Fnm1601\nHeikkila, 2010, Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation, J. Cell. Biochem., 109, 615\nClejan, 2002, Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis, J. Cell. Mol. Med., 6, 583, 10.1111\u002Fj.1582-4934.2002.tb00456.x\nLi, 2001, Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha, Microvasc. Res., 61, 253, 10.1006\u002Fmvre.2001.2304\nMackins, 2006, Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia-reperfusion, J. Clin. Invest., 116, 1063, 10.1172\u002FJCI25713\nBalcells, 1997, Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations, Am. J. Physiol., 273, H1769\nBaram, 2001, Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha, J. Immunol., 167, 4008, 10.4049\u002Fjimmunol.167.7.4008\nMayranpaa, 2006, Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion, Coron. Artery Dis., 17, 611, 10.1097\u002F01.mca.0000224420.67304.4d\nMolino, 1997, Interactions of mast cell tryptase with thrombin receptors and PAR-2, J. Biol. Chem., 272, 4043, 10.1074\u002Fjbc.272.7.4043\nLotzer, 2003, Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis, Arterioscler. Thromb. Vasc. Biol., 23, e32, 10.1161\u002F01.ATV.0000082690.23131.CB\nSpanbroek, 2003, Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis, Proc. Natl. Acad. Sci. U.S.A., 100, 1238, 10.1073\u002Fpnas.242716099\nGregor, 2011, Inflammatory mechanisms in obesity, Annu. Rev. Immunol., 29, 415, 10.1146\u002Fannurev-immunol-031210-101322\nXu, 2003, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J. Clin. Invest., 112, 1821, 10.1172\u002FJCI200319451\nShoelson, 2006, Inflammation and insulin resistance, J. Clin. Invest., 116, 1793, 10.1172\u002FJCI29069\nHotamisligil, 2006, Inflammation and metabolic disorders, Nature, 444, 860, 10.1038\u002Fnature05485\nRosen, 2006, Adipocytes as regulators of energy balance and glucose homeostasis, Nature, 444, 847, 10.1038\u002Fnature05483\nCypess, 2009, Identification and importance of brown adipose tissue in adult humans, N. Engl. J. Med., 360, 1509, 10.1056\u002FNEJMoa0810780\nTilg, 2006, Adipocytokines: mediators linking adipose tissue, inflammation and immunity, Nat. Rev. Immunol., 6, 772, 10.1038\u002Fnri1937\nKoon, 2009, Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2, 4,6,-trinitrobenzensulphonic acid-induced colitis, Proc. Natl. Acad. Sci. U.S.A., 106, 8766, 10.1073\u002Fpnas.0903499106\nTheoharides, 2008, Allergic inflammation and adipocytokines, Int. J. Immunopathol. Pharmacol., 21, 1, 10.1177\u002F039463200802100101\nSick, 2010, Advanced glycation end products (AGEs) activate mast cells, Br. J. Pharmacol., 161, 442, 10.1111\u002Fj.1476-5381.2010.00905.x\nWeisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J. Clin. Invest., 112, 1796, 10.1172\u002FJCI200319246\nFeuerer, 2009, Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters, Nat Med., 15, 930, 10.1038\u002Fnm.2002\nMilanski, 2009, Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity, J. Neurosci., 29, 359, 10.1523\u002FJNEUROSCI.2760-08.2009\nSchroder, 2010, The NLRP3 inflammasome: a sensor for metabolic danger?, Science, 327, 296, 10.1126\u002Fscience.1184003\nTsukumo, 2007, Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance, Diabetes, 56, 1986, 10.2337\u002Fdb06-1595\nLiu, 2009, Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice, Nat. Med., 15, 940, 10.1038\u002Fnm.1994\nHotamisligil, 1993, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science, 259, 87, 10.1126\u002Fscience.7678183\nUysal, 1997, Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function, Nature, 389, 610, 10.1038\u002F39335\nFarooqi, 2002, Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\u002Fmetabolic dysfunction of human congenital leptin deficiency, J. Clin. Invest., 110, 1093, 10.1172\u002FJCI0215693\nTaildeman, 2009, Human mast cells express leptin and leptin receptors, Histochem. Cell Biol., 131, 703, 10.1007\u002Fs00418-009-0575-3\nPang, 2008, Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity, Am. J. Physiol. Endocrinol. Metab., 295, E313, 10.1152\u002Fajpendo.90296.2008\nRupnick, 2002, Adipose tissue mass can be regulated through the vasculature, Proc. Natl. Acad. Sci. U.S.A., 99, 10730, 10.1073\u002Fpnas.162349799\nNedvidkova, 2005, Adiponectin, an adipocyte-derived protein, Physiol. Res., 54, 133, 10.33549\u002Fphysiolres.930600\nSeres, 2004, Corticotropin-releasing hormone system in human adipose tissue, J. Clin. Endocrinol. Metab., 89, 965, 10.1210\u002Fjc.2003-031299\nTheoharides, 2004, Mast cells as targets of corticotropin-releasing factor and related peptides, Trends Pharmacol. Sci., 25, 563, 10.1016\u002Fj.tips.2004.09.007\nWiner, 2009, Normalization of obesity-associated insulin resistance through immunotherapy, Nat. Med., 15, 921, 10.1038\u002Fnm.2001\nNatarajan, 2010, Could direct inhibition of inflammation be the “next big thing” in treating atherosclerosis?, Arterioscler. Thromb. Vasc. Biol., 30, 2081, 10.1161\u002FATVBAHA.110.213793\nStanley, 2011, TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome, J. Clin. Endocrinol. Metab., 96, E146, 10.1210\u002Fjc.2010-1170\nKolak, 2007, Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 92, 720, 10.1210\u002Fjc.2006-1465\nPeraldi, 1997, Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling, J. Clin. Invest., 100, 1863, 10.1172\u002FJCI119715\nRumore, 2010, Potential role of salicylates in type 2 diabetes, Ann. Pharmacother., 44, 1207, 10.1345\u002Faph.1M483\nJain, 2005, Anti-inflammatory effects of statins: clinical evidence and basic mechanisms, Nat. Rev. Drug Discov., 4, 977, 10.1038\u002Fnrd1901\nOkayama, 1992, Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine, Clin. Exp. Allergy, 22, 401, 10.1111\u002Fj.1365-2222.1992.tb03102.x\nKempuraj, 2003, Azelastine inhibits secretion of IL-6, TNF-a and IL-8 as well as NF-kB activation and intracellular calcium ion levels in normal human mast cells, Int. Arch. Allergy Immunol., 132, 231, 10.1159\u002F000074304\nVasiadi, 2010, Rupatadine inhibits pro-inflammatory mediator secretion from human mast cells triggered by different stimuli, Clin. Exp. Allergy, 151, 38\nLevi, 2000, Histamine H3-receptors: a new frontier in myocardial ischemia, J. Pharmacol. Exp. Ther., 292, 825\nTakai, 2011, Targets of chymase inhibitors, Expert. Opin. Ther. Targets, 15, 519, 10.1517\u002F14728222.2011.555401\nCairns, 2005, Inhibitors of mast cell tryptase beta as therapeutics for the treatment of asthma and inflammatory disorders, Pulm. Pharmacol. Ther., 18, 55, 10.1016\u002Fj.pupt.2004.09.032\nMontecucco, 2010, New evidence for nicotinic acid treatment to reduce atherosclerosis, Expert Rev. Cardiovasc. Ther., 8, 1457, 10.1586\u002Ferc.10.116\nJacobson, 2010, A “hot” topic in dyslipidemia management--“how to beat a flush”: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention, Mayo Clin. Proc., 85, 365, 10.4065\u002Fmcp.2009.0535\nPapaliodis, 2008, Niacin-induced “flush” involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model, J. Pharmacol. Exp. Ther., 327, 665, 10.1124\u002Fjpet.108.141333\nPapaliodis, 2008, The flavonoid luteolin inhibits niacin-induced flush, Br. J. Pharmacol., 153, 1382, 10.1038\u002Fsj.bjp.0707668\nKalogeromitros, 2008, A quercetin containing supplement reduces niacin-induced flush in humans, Int. J. Immunopathol. Pharmacol., 21, 509, 10.1177\u002F039463200802100304\nMiddleton, 2000, The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer, Pharmacol. Rev., 52, 673\nKempuraj, 2005, Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells, Br. J. Pharmacol., 145, 934, 10.1038\u002Fsj.bjp.0706246\nAzevedo, 2010, Ursolic acid and luteolin-7-glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase-3, Phytother. Res., 24, S220, 10.1002\u002Fptr.3118\nDeqiu, 2011, Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium, Biochimie, 93, 506, 10.1016\u002Fj.biochi.2010.11.002\nAndo, 2009, Luteolin, a food-derived flavonoid, suppresses adipocyte-dependent activation of macrophages by inhibiting JNK activation, FEBS Lett., 583, 3649, 10.1016\u002Fj.febslet.2009.10.045\nWootten, 2011, Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids, J. Pharmacol. Exp. Ther., 336, 540, 10.1124\u002Fjpet.110.176362\n2011, Am. Heart J., 161, 538, 10.1016\u002Fj.ahj.2010.12.007\n2011, Am. Heart J., 161\nBruckert, 2010, Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis, Atherosclerosis, 210, 353, 10.1016\u002Fj.atherosclerosis.2009.12.023\nShehadah, 2010, Niaspan treatment induces neuroprotection after stroke, Neurobiol Dis., 40, 277, 10.1016\u002Fj.nbd.2010.05.034\nChen, 2009, Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke, J Cereb Blood Flow Metab., 29, 911, 10.1038\u002Fjcbfm.2009.11",{"VOID":721},"10.1016\u002Fj.tips.2011.05.005","2024-09-05T05:02:28.130+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165614711000940",[725,777,797,810,830,843],{"id":726,"sortIndex":19,"researcher":18,"roles":727,"affiliations":728,"properties":774,"displayName":776,"givenName":18,"familyName":18},"6b2aa04b-e5f7-4ddf-9859-8119b3b6430c",[119],[729,737,746,755,764],{"id":730,"sortIndex":19,"affiliation":731,"properties":18},"953b80e7-f6f2-4899-be57-ce714dff3bd9",{"id":730,"createTime":18,"updateTime":18,"relativeEntities":732,"slug":18,"properties":733,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":736,"statistic":18},[],{"title":734},{"VI":735},"Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, Boston, MA 02111, USA",[],{"id":738,"sortIndex":136,"affiliation":739,"properties":745},"d431b7e9-1a8b-484e-abd1-59220ac98029",{"id":738,"createTime":18,"updateTime":18,"relativeEntities":740,"slug":18,"properties":741,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":744,"statistic":18},[],{"title":742},{"VI":743},"Department of Biochemistry, Tufts University School of Medicine, Boston, MA, USA",[],{},{"id":747,"sortIndex":152,"affiliation":748,"properties":754},"2178e136-8341-4c7b-b35a-5d50a41dd253",{"id":747,"createTime":18,"updateTime":18,"relativeEntities":749,"slug":18,"properties":750,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":753,"statistic":18},[],{"title":751},{"VI":752},"Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA",[],{},{"id":756,"sortIndex":166,"affiliation":757,"properties":763},"6f574cd8-9da2-43a5-a30d-ba00bf68c7f2",{"id":756,"createTime":18,"updateTime":18,"relativeEntities":758,"slug":18,"properties":759,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":762,"statistic":18},[],{"title":760},{"VI":761},"Endocrine Division, Second Department of Internal Medicine, Attikon General Hospital, Athens University Medical School, Athens, Greece",[],{},{"id":765,"sortIndex":766,"affiliation":767,"properties":773},"02773559-5124-4c2f-8bd7-6d18c5a5c832",4,{"id":765,"createTime":18,"updateTime":18,"relativeEntities":768,"slug":18,"properties":769,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":772,"statistic":18},[],{"title":770},{"VI":771},"Allergy Clinical Research Center, Allergy Section, Attikon General Hospital, Athens University Medical School, Athens, Greece",[],{},{"title":775},{"VI":776},"Theoharis C. Theoharides",{"id":778,"sortIndex":136,"researcher":18,"roles":779,"affiliations":780,"properties":794,"displayName":796,"givenName":18,"familyName":18},"01d058e0-7a16-4824-9dd2-989e090edadf",[119],[781,787],{"id":730,"sortIndex":19,"affiliation":782,"properties":18},{"id":730,"createTime":18,"updateTime":18,"relativeEntities":783,"slug":18,"properties":784,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":786,"statistic":18},[],{"title":785},{"VI":735},[],{"id":765,"sortIndex":136,"affiliation":788,"properties":793},{"id":765,"createTime":18,"updateTime":18,"relativeEntities":789,"slug":18,"properties":790,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":792,"statistic":18},[],{"title":791},{"VI":771},[],{},{"title":795},{"VI":796},"Nikolaos Sismanopoulos",{"id":798,"sortIndex":152,"researcher":18,"roles":799,"affiliations":800,"properties":807,"displayName":809,"givenName":18,"familyName":18},"4794a61b-b136-4017-97ee-dd632a7995b8",[119],[801],{"id":730,"sortIndex":19,"affiliation":802,"properties":18},{"id":730,"createTime":18,"updateTime":18,"relativeEntities":803,"slug":18,"properties":804,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":806,"statistic":18},[],{"title":805},{"VI":735},[],{"title":808},{"VI":809},"Danae-Anastasia Delivanis",{"id":811,"sortIndex":166,"researcher":18,"roles":812,"affiliations":813,"properties":827,"displayName":829,"givenName":18,"familyName":18},"854e9a34-aa10-4245-b5a7-001ebff9efe0",[119],[814,820],{"id":730,"sortIndex":19,"affiliation":815,"properties":18},{"id":730,"createTime":18,"updateTime":18,"relativeEntities":816,"slug":18,"properties":817,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":819,"statistic":18},[],{"title":818},{"VI":735},[],{"id":738,"sortIndex":136,"affiliation":821,"properties":826},{"id":738,"createTime":18,"updateTime":18,"relativeEntities":822,"slug":18,"properties":823,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":825,"statistic":18},[],{"title":824},{"VI":743},[],{},{"title":828},{"VI":829},"Bodi Zhang",{"id":831,"sortIndex":766,"researcher":18,"roles":832,"affiliations":833,"properties":840,"displayName":842,"givenName":18,"familyName":18},"e26c16bf-be42-40a5-90d9-c4e6e3116468",[119],[834],{"id":756,"sortIndex":19,"affiliation":835,"properties":18},{"id":756,"createTime":18,"updateTime":18,"relativeEntities":836,"slug":18,"properties":837,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":839,"statistic":18},[],{"title":838},{"VI":761},[],{"title":841},{"VI":842},"Erifili E. Hatziagelaki",{"id":844,"sortIndex":845,"researcher":18,"roles":846,"affiliations":847,"properties":854,"displayName":856,"givenName":18,"familyName":18},"cd615681-29dd-442e-bcc0-6bd681c00847",5,[119],[848],{"id":765,"sortIndex":19,"affiliation":849,"properties":18},{"id":765,"createTime":18,"updateTime":18,"relativeEntities":850,"slug":18,"properties":851,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":853,"statistic":18},[],{"title":852},{"VI":771},[],{"title":855},{"VI":856},"Dimitrios Kalogeromitros",{"url":723,"publisher":858,"properties":903},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":859,"slug":10,"properties":860,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":863,"manageAffiliations":872,"indexDatabases":888,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":861,"title":862},{"VOID":13},{"EN":15},[864,868],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":865,"label":866,"description":867,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":869,"label":870,"description":871,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[873,878,883],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":874,"slug":18,"properties":875,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":877,"statistic":18},[],{"title":876},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":879,"slug":18,"properties":880,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":882,"statistic":18},[],{"title":881},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":884,"slug":18,"properties":885,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":887,"statistic":18},[],{"title":886},{"EN":53},[],[889,896],{"id":57,"indexDatabase":890,"url":70,"indexYears":18,"academicFieldIds":895,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":891,"label":892,"description":893,"key":66,"publicationTags":894,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":897,"url":85,"indexYears":86,"academicFieldIds":902,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":898,"label":899,"description":900,"key":82,"publicationTags":901,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":904,"volume":906},{"VOID":905},"534-542",{"VOID":231},"2011-09-01","2026-08-17T22:00:05.101+00:00",[68,90],{"id":911,"createTime":912,"updateTime":913,"relativeEntities":914,"slug":915,"properties":916,"entityType":110,"verifyStatus":111,"verifyTime":928,"verifyNote":113,"languages":929,"translateLanguages":18,"viewCount":19,"primaryUrl":930,"fullTextUrl":18,"authors":931,"publicationType":180,"publisherRelationship":985,"citationCount":1037,"citationInfo":1038,"publishDate":1051,"publishYear":1039,"citationAnalyzeStatus":352,"lastCitationAnalyze":1052,"indexDatabases":1053,"openAccess":18,"references":1054,"isForceReanalyzing":239},"c445de2b-da32-44fa-8171-be1048a2c8b2","2024-09-26T09:48:16.454+00:00","2026-08-15T20:45:16.862+00:00",[],"Emerging-role-of-homo-and-heterodimerization-in-G-protein-coupled-receptor-biosynthesis-and-maturation",{"openalex":917,"mag":919,"title":921,"gsPaper":923,"pm":924,"doi":926},{"VOID":918},"W1984429646",{"VOID":920},"1984429646",{"EN":922},"Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation",{"VOID":250},{"VOID":925},"15749158",{"VOID":927},"10.1016\u002Fj.tips.2005.01.004","2024-09-26T09:48:16.453+00:00",[376],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0165614705000209",[932,949,966],{"id":933,"sortIndex":19,"researcher":18,"roles":934,"affiliations":935,"properties":944,"displayName":946,"givenName":18,"familyName":18},"82d5e621-69d2-4bdd-9af2-520b9e5f8247",[],[936],{"id":937,"sortIndex":19,"affiliation":938,"properties":18},"ecd4f450-69ad-45ad-acc2-0f825de790df",{"id":937,"createTime":18,"updateTime":18,"relativeEntities":939,"slug":18,"properties":940,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":943,"statistic":18},[],{"title":941},{"EN":942},"Cell Biology Department, Institut Cochin, 27 rue du Fg St Jacques, 75014 Paris, France",[],{"title":945,"openalex":947},{"EN":946},"Sébastien Bulenger",{"VOID":948},"A5087350385",{"id":950,"sortIndex":136,"researcher":18,"roles":951,"affiliations":952,"properties":959,"displayName":963,"givenName":18,"familyName":18},"03d4d8ba-7060-4def-a8e8-1674eec214d1",[],[953],{"id":937,"sortIndex":19,"affiliation":954,"properties":18},{"id":937,"createTime":18,"updateTime":18,"relativeEntities":955,"slug":18,"properties":956,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":958,"statistic":18},[],{"title":957},{"EN":942},[],{"orcid":960,"title":962,"openalex":964},{"VOID":961},"https:\u002F\u002Forcid.org\u002F0000-0001-9604-9973",{"EN":963},"Stéfano Marullo",{"VOID":965},"A5009704367",{"id":967,"sortIndex":152,"researcher":18,"roles":968,"affiliations":969,"properties":978,"displayName":982,"givenName":18,"familyName":18},"266ccb49-f320-45c7-ad17-c5c945cbd25d",[],[970],{"id":971,"sortIndex":19,"affiliation":972,"properties":18},"25c55d61-2292-4c2d-a356-c298eaaec04c",{"id":971,"createTime":18,"updateTime":18,"relativeEntities":973,"slug":18,"properties":974,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":977,"statistic":18},[],{"title":975},{"EN":976},"Biochemistry Department, Université de Montréal, C.P. 6128 Succursale Centre-Ville, Montréal, Québec H3C 3J7, Canada",[],{"orcid":979,"title":981,"openalex":983},{"VOID":980},"https:\u002F\u002Forcid.org\u002F0000-0003-1128-0100",{"EN":982},"Michel Bouvier",{"VOID":984},"A5086198173",{"url":18,"publisher":986,"properties":1031},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":987,"slug":10,"properties":988,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":991,"manageAffiliations":1000,"indexDatabases":1016,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":989,"title":990},{"VOID":13},{"EN":15},[992,996],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":993,"label":994,"description":995,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":997,"label":998,"description":999,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[1001,1006,1011],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":1002,"slug":18,"properties":1003,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1005,"statistic":18},[],{"title":1004},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":1007,"slug":18,"properties":1008,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1010,"statistic":18},[],{"title":1009},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":1012,"slug":18,"properties":1013,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1015,"statistic":18},[],{"title":1014},{"EN":53},[],[1017,1024],{"id":57,"indexDatabase":1018,"url":70,"indexYears":18,"academicFieldIds":1023,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":1019,"label":1020,"description":1021,"key":66,"publicationTags":1022,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":1025,"url":85,"indexYears":86,"academicFieldIds":1030,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":1026,"label":1027,"description":1028,"key":82,"publicationTags":1029,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"issue":1032,"pages":1033,"volume":1035},{"VOID":480},{"VOID":1034},"131-137",{"VOID":1036},"26",435,{"total":1037,"publishYear":1039,"statisticByYear":1040},2005,{"2012":1041,"2013":1042,"2014":1043,"2015":1044,"2016":1045,"2017":1046,"2018":1047,"2019":1048,"2020":1046,"2021":1049,"2022":1049,"2023":1050,"2024":766},24,25,26,6,7,11,12,16,10,8,"2005-03-01","2026-08-15T20:45:16.861+00:00",[68,90],[1055,1059,1063,1067,1071,1075,1079,1083,1087,1091,1095,1099,1103,1107,1111,1115,1119,1123,1127,1131,1135,1139,1143,1147,1151,1155,1159,1163,1167,1171,1175,1179,1183,1187,1191,1195,1199,1203,1207,1211,1215,1219,1223,1227,1231,1235,1239,1243,1247,1251,1255,1259,1263,1267,1271,1275,1279,1283,1287,1291,1295,1299,1303,1307,1311,1315,1319,1323,1327,1331,1335,1339,1343,1347,1351,1355,1359,1363,1367,1371,1375,1379,1383,1387,1391,1395,1399,1403,1407,1411],{"id":18,"text":1056,"url":18,"identifiers":1057},"Bouvier, 2001, Oligomerization of G-protein-coupled transmitter receptors, Nat. Rev. Neurosci., 2, 274, 10.1038\u002F35067575",{"doi":1058},"10.1038\u002F35067575",{"id":18,"text":1060,"url":18,"identifiers":1061},"Kroeger, 2003, G-protein coupled receptor oligomerization in neuroendocrine pathways, Front. Neuroendocrinol., 24, 254, 10.1016\u002Fj.yfrne.2003.10.002",{"doi":1062},"10.1016\u002Fj.yfrne.2003.10.002",{"id":18,"text":1064,"url":18,"identifiers":1065},"Breitwieser, 2004, G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling, Circ. Res., 94, 17, 10.1161\u002F01.RES.0000110420.68526.19",{"doi":1066},"10.1161\u002F01.RES.0000110420.68526.19",{"id":18,"text":1068,"url":18,"identifiers":1069},"Bai, 2004, Dimerization of G-protein-coupled receptors: roles in signal transduction, Cell. Signal., 16, 175, 10.1016\u002FS0898-6568(03)00128-1",{"doi":1070},"10.1016\u002FS0898-6568(03)00128-1",{"id":18,"text":1072,"url":18,"identifiers":1073},"Marshall, 1999, GABAB receptors - the first 7TM heterodimers, Trends Pharmacol. Sci., 20, 396, 10.1016\u002FS0165-6147(99)01383-8",{"doi":1074},"10.1016\u002FS0165-6147(99)01383-8",{"id":18,"text":1076,"url":18,"identifiers":1077},"Angers, 2002, Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function, Annu. Rev. Pharmacol. Toxicol., 42, 409, 10.1146\u002Fannurev.pharmtox.42.091701.082314",{"doi":1078},"10.1146\u002Fannurev.pharmtox.42.091701.082314",{"id":18,"text":1080,"url":18,"identifiers":1081},"Eidne, 2002, Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells, Trends Endocrinol. Metab., 13, 415, 10.1016\u002FS1043-2760(02)00669-0",{"doi":1082},"10.1016\u002FS1043-2760(02)00669-0",{"id":18,"text":1084,"url":18,"identifiers":1085},"George, 2002, G-protein-coupled receptor oligomerization and its potential for drug discovery, Nat. Rev. Drug Discov., 1, 808, 10.1038\u002Fnrd913",{"doi":1086},"10.1038\u002Fnrd913",{"id":18,"text":1088,"url":18,"identifiers":1089},"Fotiadis, 2003, Atomic-force microscopy: rhodopsin dimers in native disc membranes, Nature, 421, 127, 10.1038\u002F421127a",{"doi":1090},"10.1038\u002F421127a",{"id":18,"text":1092,"url":18,"identifiers":1093},"Palczewski, 2000, Crystal structure of rhodopsin: a G protein-coupled receptor, Science, 289, 739, 10.1126\u002Fscience.289.5480.739",{"doi":1094},"10.1126\u002Fscience.289.5480.739",{"id":18,"text":1096,"url":18,"identifiers":1097},"Sondek, 1996, Crystal structure of a G-protein beta gamma dimer at 2.1A resolution, Nature, 379, 369, 10.1038\u002F379369a0",{"doi":1098},"10.1038\u002F379369a0",{"id":18,"text":1100,"url":18,"identifiers":1101},"Lambright, 1996, The 2.0 A crystal structure of a heterotrimeric G protein, Nature, 379, 311, 10.1038\u002F379311a0",{"doi":1102},"10.1038\u002F379311a0",{"id":18,"text":1104,"url":18,"identifiers":1105},"Hamm, 2001, How activated receptors couple to G proteins, Proc. Natl. Acad. Sci. U. S. A., 98, 4819, 10.1073\u002Fpnas.011099798",{"doi":1106},"10.1073\u002Fpnas.011099798",{"id":18,"text":1108,"url":18,"identifiers":1109},"Baneres, 2003, Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein, J. Mol. Biol., 329, 815, 10.1016\u002FS0022-2836(03)00439-X",{"doi":1110},"10.1016\u002FS0022-2836(03)00439-X",{"id":18,"text":1112,"url":18,"identifiers":1113},"Kniazeff, 2004, Closed state of both binding domains of homodimeric mGlu receptors is required for full activity, Nat. Struct. Mol. Biol., 11, 706, 10.1038\u002Fnsmb794",{"doi":1114},"10.1038\u002Fnsmb794",{"id":18,"text":1116,"url":18,"identifiers":1117},"Pin, 2003, Evolution, structure, and activation mechanism of family 3\u002FC G-protein-coupled receptors, Pharmacol. Ther., 98, 325, 10.1016\u002FS0163-7258(03)00038-X",{"doi":1118},"10.1016\u002FS0163-7258(03)00038-X",{"id":18,"text":1120,"url":18,"identifiers":1121},"Zeng, 1999, Identification and molecular characterization of m3 muscarinic receptor dimers, J. Biol. Chem., 274, 19487, 10.1074\u002Fjbc.274.27.19487",{"doi":1122},"10.1074\u002Fjbc.274.27.19487",{"id":18,"text":1124,"url":18,"identifiers":1125},"McVey, 2001, Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta -opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy, J. Biol. Chem., 276, 14092, 10.1074\u002Fjbc.M008902200",{"doi":1126},"10.1074\u002Fjbc.M008902200",{"id":18,"text":1128,"url":18,"identifiers":1129},"Overton, 2000, G-protein-coupled receptors function as oligomers in vivo, Curr. Biol., 10, 341, 10.1016\u002FS0960-9822(00)00386-9",{"doi":1130},"10.1016\u002FS0960-9822(00)00386-9",{"id":18,"text":1132,"url":18,"identifiers":1133},"Ayoub, 2002, Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer, J. Biol. Chem., 277, 21522, 10.1074\u002Fjbc.M200729200",{"doi":1134},"10.1074\u002Fjbc.M200729200",{"id":18,"text":1136,"url":18,"identifiers":1137},"Issafras, 2002, Constitutive agonist-independent CCR5 oligomerization and antibody- mediated clustering occurring at physiological levels of receptors, J. Biol. Chem., 277, 34666, 10.1074\u002Fjbc.M202386200",{"doi":1138},"10.1074\u002Fjbc.M202386200",{"id":18,"text":1140,"url":18,"identifiers":1141},"Jensen, 2002, Probing intermolecular protein-protein interactions in the calcium-sensing receptor homodimer using bioluminescence resonance energy transfer (BRET), Eur. J. Biochem., 269, 5076, 10.1046\u002Fj.1432-1033.2002.03218.x",{"doi":1142},"10.1046\u002Fj.1432-1033.2002.03218.x",{"id":18,"text":1144,"url":18,"identifiers":1145},"Terrillon, 2003, Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis, Mol. Endocrinol., 17, 677, 10.1210\u002Fme.2002-0222",{"doi":1146},"10.1210\u002Fme.2002-0222",{"id":18,"text":1148,"url":18,"identifiers":1149},"Babcock, 2003, Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor, J. Biol. Chem., 278, 3378, 10.1074\u002Fjbc.M210140200",{"doi":1150},"10.1074\u002Fjbc.M210140200",{"id":18,"text":1152,"url":18,"identifiers":1153},"Salahpour, 2004, Homodimerization of the {beta}2-Adrenergic Receptor as a Prerequisite for Cell Surface Targeting, J. Biol. Chem., 279, 33390, 10.1074\u002Fjbc.M403363200",{"doi":1154},"10.1074\u002Fjbc.M403363200",{"id":18,"text":1156,"url":18,"identifiers":1157},"Agnati, 2003, Molecular mechanisms and therapeutical implications of intramembrane receptor\u002Freceptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons, Pharmacol. Rev., 55, 509, 10.1124\u002Fpr.55.3.2",{"doi":1158},"10.1124\u002Fpr.55.3.2",{"id":18,"text":1160,"url":18,"identifiers":1161},"Margeta-Mitrovic, 2000, A trafficking checkpoint controls GABA(B) receptor heterodimerization, Neuron, 27, 97, 10.1016\u002FS0896-6273(00)00012-X",{"doi":1162},"10.1016\u002FS0896-6273(00)00012-X",{"id":18,"text":1164,"url":18,"identifiers":1165},"Bockaert, 1999, Molecular tinkering of G protein-coupled receptors: an evolutionary success, EMBO J., 18, 1723, 10.1093\u002Femboj\u002F18.7.1723",{"doi":1166},"10.1093\u002Femboj\u002F18.7.1723",{"id":18,"text":1168,"url":18,"identifiers":1169},"Hague, 2004, Cell surface expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors, J. Biol. Chem., 279, 15541, 10.1074\u002Fjbc.M314014200",{"doi":1170},"10.1074\u002Fjbc.M314014200",{"id":18,"text":1172,"url":18,"identifiers":1173},"Hague, 2004, Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor, Proc. Natl. Acad. Sci. U. S. A., 101, 13672, 10.1073\u002Fpnas.0403854101",{"doi":1174},"10.1073\u002Fpnas.0403854101",{"id":18,"text":1176,"url":18,"identifiers":1177},"Nelson, 2001, Mammalian sweet taste receptors, Cell, 106, 381, 10.1016\u002FS0092-8674(01)00451-2",{"doi":1178},"10.1016\u002FS0092-8674(01)00451-2",{"id":18,"text":1180,"url":18,"identifiers":1181},"Nelson, 2002, An amino-acid taste receptor, Nature, 416, 199, 10.1038\u002Fnature726",{"doi":1182},"10.1038\u002Fnature726",{"id":18,"text":1184,"url":18,"identifiers":1185},"Benkirane, 1997, Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32, J. Biol. Chem., 272, 30603, 10.1074\u002Fjbc.272.49.30603",{"doi":1186},"10.1074\u002Fjbc.272.49.30603",{"id":18,"text":1188,"url":18,"identifiers":1189},"Shioda, 2001, Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5, J. Virol., 75, 3462, 10.1128\u002FJVI.75.7.3462-3468.2001",{"doi":1190},"10.1128\u002FJVI.75.7.3462-3468.2001",{"id":18,"text":1192,"url":18,"identifiers":1193},"Kaykas, 2004, Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization, Nat. Cell Biol., 6, 52, 10.1038\u002Fncb1081",{"doi":1194},"10.1038\u002Fncb1081",{"id":18,"text":1196,"url":18,"identifiers":1197},"Overton, 2003, Oligomerization, biogenesis, and signaling is promoted by a glycophorin A-like dimerization motif in transmembrane domain 1 of a yeast G protein-coupled receptor, J. Biol. Chem., 278, 49369, 10.1074\u002Fjbc.M308654200",{"doi":1198},"10.1074\u002Fjbc.M308654200",{"id":18,"text":1200,"url":18,"identifiers":1201},"Hebert, 1996, A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation, J. Biol. Chem., 271, 16384, 10.1074\u002Fjbc.271.27.16384",{"doi":1202},"10.1074\u002Fjbc.271.27.16384",{"id":18,"text":1204,"url":18,"identifiers":1205},"Bass, 1998, Folding of insulin receptor monomers is facilitated by the molecular chaperones calnexin and calreticulin and impaired by rapid dimerization, J. Cell Biol., 141, 637, 10.1083\u002Fjcb.141.3.637",{"doi":1206},"10.1083\u002Fjcb.141.3.637",{"id":18,"text":1208,"url":18,"identifiers":1209},"Wu, 2004, Proreceptor dimerization is required for insulin receptor post-translational processing, J. Biol. Chem., 279, 25765, 10.1074\u002Fjbc.M314281200",{"doi":1210},"10.1074\u002Fjbc.M314281200",{"id":18,"text":1212,"url":18,"identifiers":1213},"Gent, 2002, Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis, Proc. Natl. Acad. Sci. U. S. A., 99, 9858, 10.1073\u002Fpnas.152294299",{"doi":1214},"10.1073\u002Fpnas.152294299",{"id":18,"text":1216,"url":18,"identifiers":1217},"Gilboa, 1998, Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane, J. Cell Biol., 140, 767, 10.1083\u002Fjcb.140.4.767",{"doi":1218},"10.1083\u002Fjcb.140.4.767",{"id":18,"text":1220,"url":18,"identifiers":1221},"Zerangue, 1999, A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels, Neuron, 22, 537, 10.1016\u002FS0896-6273(00)80708-4",{"doi":1222},"10.1016\u002FS0896-6273(00)80708-4",{"id":18,"text":1224,"url":18,"identifiers":1225},"Papazian, 1999, Potassium channels: some assembly required, Neuron, 23, 7, 10.1016\u002FS0896-6273(00)80746-1",{"doi":1226},"10.1016\u002FS0896-6273(00)80746-1",{"id":18,"text":1228,"url":18,"identifiers":1229},"Reddy, 1998, Assembly, sorting, and exit of oligomeric proteins from the endoplasmic reticulum, Bioessays, 20, 546, 10.1002\u002F(SICI)1521-1878(199807)20:7\u003C546::AID-BIES5>3.0.CO;2-I",{"doi":1230},"10.1002\u002F(SICI)1521-1878(199807)20:7\u003C546::AID-BIES5>3.0.CO;2-I",{"id":18,"text":1232,"url":18,"identifiers":1233},"Ellgaard, 2003, Quality control in the endoplasmic reticulum, Nat. Rev. Mol. Cell Biol., 4, 181, 10.1038\u002Fnrm1052",{"doi":1234},"10.1038\u002Fnrm1052",{"id":18,"text":1236,"url":18,"identifiers":1237},"Yuan, 2003, 14-3-3 dimers probe the assembly status of multimeric membrane proteins, Curr. Biol., 13, 638, 10.1016\u002FS0960-9822(03)00208-2",{"doi":1238},"10.1016\u002FS0960-9822(03)00208-2",{"id":18,"text":1240,"url":18,"identifiers":1241},"Prezeau, 1999, The zeta isoform of 14-3-3 proteins interacts with the third intracellular loop of different alpha2-adrenergic receptor subtypes, J. Biol. Chem., 274, 13462, 10.1074\u002Fjbc.274.19.13462",{"doi":1242},"10.1074\u002Fjbc.274.19.13462",{"id":18,"text":1244,"url":18,"identifiers":1245},"Couve, 2001, Association of GABA(B) receptors and members of the 14-3-3 family of signaling proteins, Mol. Cell. Neurosci., 17, 317, 10.1006\u002Fmcne.2000.0938",{"doi":1246},"10.1006\u002Fmcne.2000.0938",{"id":18,"text":1248,"url":18,"identifiers":1249},"Tazawa, 2003, Interaction of the parathyroid hormone receptor with the 14-3-3 protein, Biochim. Biophys. Acta, 1620, 32, 10.1016\u002FS0304-4165(02)00503-2",{"doi":1250},"10.1016\u002FS0304-4165(02)00503-2",{"id":18,"text":1252,"url":18,"identifiers":1253},"Baker, 1994, The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex in vivo with its protein target rhodopsin, EMBO J., 13, 4886, 10.1002\u002Fj.1460-2075.1994.tb06816.x",{"doi":1254},"10.1002\u002Fj.1460-2075.1994.tb06816.x",{"id":18,"text":1256,"url":18,"identifiers":1257},"Chapple, 2003, The chaperone environment at the cytoplasmic face of the endoplasmic reticulum can modulate rhodopsin processing and inclusion formation, J. Biol. Chem., 278, 19087, 10.1074\u002Fjbc.M212349200",{"doi":1258},"10.1074\u002Fjbc.M212349200",{"id":18,"text":1260,"url":18,"identifiers":1261},"Bermak, 2001, Regulation of transport of the dopamine D1 receptor by a new membrane- associated ER protein, Nat. Cell Biol., 3, 492, 10.1038\u002F35074561",{"doi":1262},"10.1038\u002F35074561",{"id":18,"text":1264,"url":18,"identifiers":1265},"McLatchie, 1998, RAMPs regulate the transport and ligand specificity of the calcitonin- receptor-like receptor, Nature, 393, 333, 10.1038\u002F30666",{"doi":1266},"10.1038\u002F30666",{"id":18,"text":1268,"url":18,"identifiers":1269},"Sexton, 2001, Receptor activity modifying proteins, Cell. Signal., 13, 73, 10.1016\u002FS0898-6568(00)00143-1",{"doi":1270},"10.1016\u002FS0898-6568(00)00143-1",{"id":18,"text":1272,"url":18,"identifiers":1273},"Loconto, 2003, Functional expression of murine V2R pheromone receptors involves selective association with the M10 and M1 families of MHC class Ib molecules, Cell, 112, 607, 10.1016\u002FS0092-8674(03)00153-3",{"doi":1274},"10.1016\u002FS0092-8674(03)00153-3",{"id":18,"text":1276,"url":18,"identifiers":1277},"Gimelbrant, 2001, Olfactory receptor trafficking involves conserved regulatory steps, J. Biol. Chem., 276, 7285, 10.1074\u002Fjbc.M005433200",{"doi":1278},"10.1074\u002Fjbc.M005433200",{"id":18,"text":1280,"url":18,"identifiers":1281},"Dwyer, 1998, Odorant receptor localization to olfactory cilia is mediated by ODR-4, a novel membrane-associated protein, Cell, 93, 455, 10.1016\u002FS0092-8674(00)81173-3",{"doi":1282},"10.1016\u002FS0092-8674(00)81173-3",{"id":18,"text":1284,"url":18,"identifiers":1285},"AbdAlla, 1999, Involvement of the amino terminus of the B(2) receptor in agonist- induced receptor dimerization, J. Biol. Chem., 274, 26079, 10.1074\u002Fjbc.274.37.26079",{"doi":1286},"10.1074\u002Fjbc.274.37.26079",{"id":18,"text":1288,"url":18,"identifiers":1289},"Rodriguez-Frade, 1999, The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2, Proc. Natl. Acad. Sci. U. S. A., 96, 3628, 10.1073\u002Fpnas.96.7.3628",{"doi":1290},"10.1073\u002Fpnas.96.7.3628",{"id":18,"text":1292,"url":18,"identifiers":1293},"Rocheville, 2000, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers, J. Biol. Chem., 275, 7862, 10.1074\u002Fjbc.275.11.7862",{"doi":1294},"10.1074\u002Fjbc.275.11.7862",{"id":18,"text":1296,"url":18,"identifiers":1297},"Vila-Coro, 2000, HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization, Proc. Natl. Acad. Sci. U. S. A., 97, 3388, 10.1073\u002Fpnas.050457797",{"doi":1298},"10.1073\u002Fpnas.050457797",{"id":18,"text":1300,"url":18,"identifiers":1301},"Horvat, 2001, Binding of agonist but not antagonist leads to fluorescence resonance energy transfer between intrinsically fluorescent gonadotropin-releasing hormone receptors, Mol. Endocrinol., 15, 695, 10.1210\u002Fme.15.5.695",{"doi":1302},"10.1210\u002Fme.15.5.695",{"id":18,"text":1304,"url":18,"identifiers":1305},"Terrillon, 2004, Roles of G-protein-coupled receptor dimerization, EMBO Rep., 5, 30, 10.1038\u002Fsj.embor.7400052",{"doi":1306},"10.1038\u002Fsj.embor.7400052",{"id":18,"text":1308,"url":18,"identifiers":1309},"Vilardaga, 2003, Measurement of the millisecond activation switch of G protein-coupled receptors in living cells, Nat. Biotechnol., 21, 807, 10.1038\u002Fnbt838",{"doi":1310},"10.1038\u002Fnbt838",{"id":18,"text":1312,"url":18,"identifiers":1313},"Rocheville, 2000, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity, Science, 288, 154, 10.1126\u002Fscience.288.5463.154",{"doi":1314},"10.1126\u002Fscience.288.5463.154",{"id":18,"text":1316,"url":18,"identifiers":1317},"Kroeger, 2001, Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer, J. Biol. Chem., 276, 12736, 10.1074\u002Fjbc.M011311200",{"doi":1318},"10.1074\u002Fjbc.M011311200",{"id":18,"text":1320,"url":18,"identifiers":1321},"Patel, 2002, Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells, Proc. Natl. Acad. Sci. U. S. A., 99, 3294, 10.1073\u002Fpnas.042705099",{"doi":1322},"10.1073\u002Fpnas.042705099",{"id":18,"text":1324,"url":18,"identifiers":1325},"Ayoub, 2004, Preferential formation of MT1\u002FMT2 melatonin receptor heterodimers with distinct ligand interaction properties compared to MT2 homodimers, Mol. Pharmacol., 66, 312, 10.1124\u002Fmol.104.000398",{"doi":1326},"10.1124\u002Fmol.104.000398",{"id":18,"text":1328,"url":18,"identifiers":1329},"Breit, 2004, Heterodimerization between beta 2- and beta 3-adrenergic receptors generates a beta -adrenergic signalling unit with distinct functional properties, J. Biol. Chem., 279, 28756, 10.1074\u002Fjbc.M313310200",{"doi":1330},"10.1074\u002Fjbc.M313310200",{"id":18,"text":1332,"url":18,"identifiers":1333},"AbdAlla, 2000, AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration, Nature, 407, 94, 10.1038\u002F35024095",{"doi":1334},"10.1038\u002F35024095",{"id":18,"text":1336,"url":18,"identifiers":1337},"Ciruela, 2001, Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes, J. Biol. Chem., 276, 18345, 10.1074\u002Fjbc.M006960200",{"doi":1338},"10.1074\u002Fjbc.M006960200",{"id":18,"text":1340,"url":18,"identifiers":1341},"AbdAlla, 2001, Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness, Nat. Med., 7, 1003, 10.1038\u002Fnm0901-1003",{"doi":1342},"10.1038\u002Fnm0901-1003",{"id":18,"text":1344,"url":18,"identifiers":1345},"Ramsay, 2002, Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences, Biochem. J., 365, 429, 10.1042\u002Fbj20020251",{"doi":1346},"10.1042\u002Fbj20020251",{"id":18,"text":1348,"url":18,"identifiers":1349},"Mercier, 2002, Quantitative assessment of beta 1 and beta 2-adrenergic receptor homo and hetero-dimerization by bioluminescence resonance energy transfer, J. Biol. Chem., 277, 44925, 10.1074\u002Fjbc.M205767200",{"doi":1350},"10.1074\u002Fjbc.M205767200",{"id":18,"text":1352,"url":18,"identifiers":1353},"Ray, 1999, Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca(2+) receptor critical for dimerization. Implications for function of monomeric Ca(2+) receptor, J. Biol. Chem., 274, 27642, 10.1074\u002Fjbc.274.39.27642",{"doi":1354},"10.1074\u002Fjbc.274.39.27642",{"id":18,"text":1356,"url":18,"identifiers":1357},"Kunishima, 2000, Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor, Nature, 407, 971, 10.1038\u002F35039564",{"doi":1358},"10.1038\u002F35039564",{"id":18,"text":1360,"url":18,"identifiers":1361},"Zhang, 2001, The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions, J. Biol. Chem., 276, 5316, 10.1074\u002Fjbc.M005958200",{"doi":1362},"10.1074\u002Fjbc.M005958200",{"id":18,"text":1364,"url":18,"identifiers":1365},"Pagano, 2001, C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(B) receptors, J. Neurosci., 21, 1189, 10.1523\u002FJNEUROSCI.21-04-01189.2001",{"doi":1366},"10.1523\u002FJNEUROSCI.21-04-01189.2001",{"id":18,"text":1368,"url":18,"identifiers":1369},"Cvejic, 1997, Dimerization of the delta opioid receptor: implication for a role in receptor internalization, J. Biol. Chem., 272, 26959, 10.1074\u002Fjbc.272.43.26959",{"doi":1370},"10.1074\u002Fjbc.272.43.26959",{"id":18,"text":1372,"url":18,"identifiers":1373},"Hernanz-Falcon, 2004, Identification of amino acid residues crucial for chemokine receptor dimerization, Nat. Immunol., 5, 216, 10.1038\u002Fni1027",{"doi":1374},"10.1038\u002Fni1027",{"id":18,"text":1376,"url":18,"identifiers":1377},"Lee, 2003, D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4, Biochemistry, 42, 11023, 10.1021\u002Fbi0345539",{"doi":1378},"10.1021\u002Fbi0345539",{"id":18,"text":1380,"url":18,"identifiers":1381},"Carrillo, 2004, Multiple interactions between transmembrane helices generate the oligomeric {alpha}1b-adrenoceptor, Mol. Pharmacol., 66, 1123, 10.1124\u002Fmol.104.001586",{"doi":1382},"10.1124\u002Fmol.104.001586",{"id":18,"text":1384,"url":18,"identifiers":1385},"Guo, 2003, The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer, J. Biol. Chem., 278, 4385, 10.1074\u002Fjbc.C200679200",{"doi":1386},"10.1074\u002Fjbc.C200679200",{"id":18,"text":1388,"url":18,"identifiers":1389},"Gouldson, 2001, Lipid-facing correlated mutations and dimerization in G-protein coupled receptors, Protein Eng., 14, 759, 10.1093\u002Fprotein\u002F14.10.759",{"doi":1390},"10.1093\u002Fprotein\u002F14.10.759",{"id":18,"text":1392,"url":18,"identifiers":1393},"Dean, 2001, Dimerization of G-protein-coupled receptors, J. Med. Chem., 44, 4595, 10.1021\u002Fjm010290+",{"doi":1394},"10.1021\u002Fjm010290+",{"id":18,"text":1396,"url":18,"identifiers":1397},"Filizola, 2002, Prediction of heterodimerization interfaces of G-protein coupled receptors with a new subtractive correlated mutation method, Protein Eng., 15, 881, 10.1093\u002Fprotein\u002F15.11.881",{"doi":1398},"10.1093\u002Fprotein\u002F15.11.881",{"id":18,"text":1400,"url":18,"identifiers":1401},"Jordan, 1999, G-protein-coupled receptor heterodimerization modulates receptor function, Nature, 399, 697, 10.1038\u002F21441",{"doi":1402},"10.1038\u002F21441",{"id":18,"text":1404,"url":18,"identifiers":1405},"Michaelson, 2002, Membrane trafficking of heterotrimeric G proteins via the endoplasmic reticulum and Golgi, Mol. Biol. Cell, 13, 3294, 10.1091\u002Fmbc.E02-02-0095",{"doi":1406},"10.1091\u002Fmbc.E02-02-0095",{"id":18,"text":1408,"url":18,"identifiers":1409},"Takida, 2003, Heterotrimer formation, together with isoprenylation, is required for plasma membrane targeting of Gbetagamma, J. Biol. Chem., 278, 17284, 10.1074\u002Fjbc.M213239200",{"doi":1410},"10.1074\u002Fjbc.M213239200",{"id":18,"text":1412,"url":18,"identifiers":1413},"Takida, 2004, Exocytic pathway-independent plasma membrane targeting of heterotrimeric G proteins, FEBS Lett., 567, 209, 10.1016\u002Fj.febslet.2004.04.062",{"doi":1414},"10.1016\u002Fj.febslet.2004.04.062",{"id":1416,"createTime":1417,"updateTime":1418,"relativeEntities":1419,"slug":1420,"properties":1421,"entityType":110,"verifyStatus":111,"verifyTime":1430,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1431,"fullTextUrl":18,"authors":1432,"publicationType":180,"publisherRelationship":1478,"citationCount":19,"citationInfo":1529,"publishDate":1532,"publishYear":1530,"citationAnalyzeStatus":236,"lastCitationAnalyze":1533,"indexDatabases":1534,"openAccess":18,"references":18,"isForceReanalyzing":239},"c64f7c56-3b8e-4383-8138-05fae4bac2c8","2024-02-13T04:24:12.122+00:00","2026-08-15T07:51:10.779+00:00",[],"A-subfamily-of-5-HT1D-receptor-genes",{"title":1422,"gsPaper":1424,"references":1426,"doi":1428},{"EN":1423},"A subfamily of 5-HT1D receptor genes",{"VOID":1425},"[\"4372826201504400267\"]",{"VOID":1427},"Branchek, 1991, 21\nWeinshank, R. L., Zgombick, J. M., Macchi, M., Branchek, T. A. and Hartig, P. R. Proc. Natl Acad. Sci. USA (in press).\nHamblin, 1991, Mol. Pharmacol., 40, 143\nLibert, 1989, Science, 244, 569, 10.1126\u002Fscience.2541503\nZgombick, 1991, Mol. Pharmacol., 40, 1036\nMaenhaut, 1991, Biochem. Biophys. Res. Commun., 180, 1460, 10.1016\u002FS0006-291X(05)81360-9\nJin, H. et al.J. Biol. Chem. (in press).\nVoight, 1991, EMBO J., 10, 4017, 10.1002\u002Fj.1460-2075.1991.tb04977.x\nAdham, 1992, Mol. Pharmacol., 41, 1\nHeuring, 1987, J. Neurosci., 7, 894, 10.1523\u002FJNEUROSCI.07-03-00894.1987\nWaeber, 1990, Neurochem. Res., 15, 567, 10.1007\u002FBF00973745\nHoyer, 1989, Trends Pharmacol. Sci., 10, 130, 10.1016\u002F0165-6147(89)90159-4\nMolderings, 1989, Naunyn-Schmied. Arch. Pharmacol., 340, 300, 10.1007\u002FBF00168514\nHumphrey, 1988, Br. J. Pharmacol., 94, 1123, 10.1111\u002Fj.1476-5381.1988.tb11630.x\nBond, 1989, J. Autonom. Pharmacol., 9, 201, 10.1111\u002Fj.1474-8673.1989.tb00211.x\nHoyer, 1991, 117\nLimberger, 1991, Naunyn-Schmied. Arch. Pharmacol., 343, 353, 10.1007\u002FBF00179039\nMaroteaux, L. et al.Proc. Natl Acad. Sci. USA (in press).\nHerrick-Davis, 1988, J. Neurochem., 50, 1624, 10.1111\u002Fj.1471-4159.1988.tb03052.x\nBerendsen, 1991, Eur. J. Pharmacol., 194, 201, 10.1016\u002F0014-2999(91)90106-Z\nSchlicker, 1989, Naunyn-Schmied. Arch. Pharmacol., 340, 45, 10.1007\u002FBF00169206\nMolderings, 1990, Naunyn-Schmied. Arch. Pharmacol., 342, 371, 10.1007\u002FBF00169451\nTadipatri, 1991, Br. J. Pharmacol., 104, 887, 10.1111\u002Fj.1476-5381.1991.tb12522.x\nSaxena, 1991, Trends Pharmacol. Sci., 12, 223, 10.1016\u002F0165-6147(91)90556-8\nSahin-Erdemli, 1991, Br. J. Pharmacol., 102, 386, 10.1111\u002Fj.1476-5381.1991.tb12183.x\nConnor, 1989, Br. J. Pharmacol., 96, 379, 10.1111\u002Fj.1476-5381.1989.tb11828.x\nHartig, 1989, Trends Pharmacol. Sci., 10, 64, 10.1016\u002F0165-6147(89)90080-1\nJulius, 1991, Annu. Rev. Neurosci., 14, 335, 10.1146\u002Fannurev.ne.14.030191.002003\nMaricq, 1991, Science, 254, 432, 10.1126\u002Fscience.1718042\nHoftman, 1991, Science, 254, 579, 10.1126\u002Fscience.1948036\nSaudou, 1992, EMBO J., 11, 7, 10.1002\u002Fj.1460-2075.1992.tb05021.x\nHen, 1992, Trends Pharmacol. Sci., 13, 160, 10.1016\u002F0165-6147(92)90054-A\nGuan, X-M., Peroutka, S. J. and Kobilka, B. M. Mol Pharmacol. (in press).\nSuryanarayana, 1991, J. Biol. Chem., 266, 15488, 10.1016\u002FS0021-9258(18)98642-4",{"VOID":1429},"10.1016\u002F0165-6147(92)90053-9","2024-06-24T16:27:42.081+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0165614792900539",[1433,1448,1463],{"id":1434,"sortIndex":19,"researcher":18,"roles":1435,"affiliations":1436,"properties":1445,"displayName":1447,"givenName":18,"familyName":18},"d6d66a4c-5252-4a86-bc5a-9e314cd991d7",[119],[1437],{"id":1438,"sortIndex":19,"affiliation":1439,"properties":18},"fb583f07-d933-4ac9-ad2e-7118b8315104",{"id":1438,"createTime":18,"updateTime":18,"relativeEntities":1440,"slug":18,"properties":1441,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1444,"statistic":18},[],{"title":1442},{"VI":1443},"P. R. Hartig is Vice President for Research, 215 College Road, Paramus, NJ 07562, USA",[],{"title":1446},{"VI":1447},"Paul R. Hartig",{"id":1449,"sortIndex":136,"researcher":18,"roles":1450,"affiliations":1451,"properties":1460,"displayName":1462,"givenName":18,"familyName":18},"0702f281-6d89-44a1-9e30-1255c2466cd7",[119],[1452],{"id":1453,"sortIndex":19,"affiliation":1454,"properties":18},"8553f0d8-0987-49b1-add1-f1c0718daa10",{"id":1453,"createTime":18,"updateTime":18,"relativeEntities":1455,"slug":18,"properties":1456,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1459,"statistic":18},[],{"title":1457},{"VI":1458},"T. A. Branchek is Director of Molecular Pharmacology, 215 College Road, Paramus, NJ 07562, USA",[],{"title":1461},{"VI":1462},"Theresa A. Branchek",{"id":1464,"sortIndex":152,"researcher":18,"roles":1465,"affiliations":1466,"properties":1475,"displayName":1477,"givenName":18,"familyName":18},"b8cf08a3-a3de-4eb1-9d70-8252af2efad1",[119],[1467],{"id":1468,"sortIndex":19,"affiliation":1469,"properties":18},"1ebecd95-e95b-4df1-8e90-c95087f4ce63",{"id":1468,"createTime":18,"updateTime":18,"relativeEntities":1470,"slug":18,"properties":1471,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1474,"statistic":18},[],{"title":1472},{"VI":1473},"R. L. Weinshank is Director of Cell and Molecular Biology, at Synaptic Pharmaceuticals (formerly Neurogenetic Corporation), 215 College Road, Paramus, NJ 07562, USA",[],{"title":1476},{"VI":1477},"Richard L. Weinshank",{"url":1431,"publisher":1479,"properties":1524},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1480,"slug":10,"properties":1481,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1484,"manageAffiliations":1493,"indexDatabases":1509,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1482,"title":1483},{"VOID":13},{"EN":15},[1485,1489],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1486,"label":1487,"description":1488,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1490,"label":1491,"description":1492,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[1494,1499,1504],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":1495,"slug":18,"properties":1496,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1498,"statistic":18},[],{"title":1497},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":1500,"slug":18,"properties":1501,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1503,"statistic":18},[],{"title":1502},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":1505,"slug":18,"properties":1506,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1508,"statistic":18},[],{"title":1507},{"EN":53},[],[1510,1517],{"id":57,"indexDatabase":1511,"url":70,"indexYears":18,"academicFieldIds":1516,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":1512,"label":1513,"description":1514,"key":66,"publicationTags":1515,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":1518,"url":85,"indexYears":86,"academicFieldIds":1523,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":1519,"label":1520,"description":1521,"key":82,"publicationTags":1522,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":1525,"volume":1527},{"VOID":1526},"152-159",{"VOID":1528},"13",{"total":19,"publishYear":1530,"statisticByYear":1531},1992,{},"1992-01-01","2026-08-15T07:51:10.778+00:00",[68,90],{"id":1536,"createTime":1537,"updateTime":1538,"relativeEntities":1539,"slug":1540,"properties":1541,"entityType":110,"verifyStatus":111,"verifyTime":1550,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1551,"fullTextUrl":18,"authors":1552,"publicationType":180,"publisherRelationship":1608,"citationCount":18,"citationInfo":18,"publishDate":1659,"publishYear":1660,"citationAnalyzeStatus":1661,"lastCitationAnalyze":18,"indexDatabases":1662,"openAccess":18,"references":18,"isForceReanalyzing":239},"7337aec1-06d7-4ee4-8157-00233fcca871","2023-12-28T07:43:11.538+00:00","2026-07-27T17:55:47.561+00:00",[],"The-nicotinic-acetylcholine-receptor-Molecular-architecture-of-a-ligand-regulated-ion-channel",{"title":1542,"gsPaper":1544,"references":1546,"doi":1548},{"EN":1543},"The nicotinic acetylcholine receptor: Molecular architecture of a ligand-regulated ion channel",{"VOID":1545},"[\"7991607990091945744\"]",{"VOID":1547},"Montal, 1986, 157\nPopot, 1984, Physiol. Rev., 64, 1162, 10.1152\u002Fphysrev.1984.64.4.1162\nBrisson, 1985, Nature, 315, 474, 10.1038\u002F315474a0\nKubalek, 1987, J. Cell Biol., 105, 9, 10.1083\u002Fjcb.105.1.9\nNoda, 1983, Nature, 302, 528, 10.1038\u002F302528a0\nStroud, 1985, Annu. Rev. Cell Biol., 1, 317, 10.1146\u002Fannurev.cb.01.110185.001533\nHeidmann, 1986, Science, 234, 866, 10.1126\u002Fscience.3022377\nMishina, 1986, Nature, 321, 406, 10.1038\u002F321406a0\nGoldman, 1987, Cell, 48, 965, 10.1016\u002F0092-8674(87)90705-7\nHermans-Borgmeyer, 1986, EMBO J., 5, 1503, 10.1002\u002Fj.1460-2075.1986.tb04389.x\nNoda, 1982, Nature, 299, 793, 10.1038\u002F299793a0\nClaudio, 1983, 80, 1111\nDevillers-Thiery, 1983, 80, 2067\nGuy, 1984, Biophys. J., 45, 249, 10.1016\u002FS0006-3495(84)84152-1\nFiner-Moore, 1984, 81, 155\nLindstrom, 1986, Trends Neurosci., 9, 401, 10.1016\u002F0166-2236(86)90128-1\nGiraudat, 1985, Biochemistry, 24, 3121, 10.1021\u002Fbi00334a008\nMacCrea, 1986, Biophys. J., 49, 355a\nDunn, 1987, Biochem. Biophys. Res. Commun., 139, 830, 10.1016\u002FS0006-291X(86)80065-1\nKarlin, 1980, 191\nTzartos, 1984, J. Biol. Chem., 259, 11512, 10.1016\u002FS0021-9258(18)90892-6\nMishina, 1984, Nature, 307, 604, 10.1038\u002F307604a0\nCulver, 1984, J. Biol. Chem., 259, 3763, 10.1016\u002FS0021-9258(17)43160-7\nKurosaki, 1987, FEBS Lett., 214, 253, 10.1016\u002F0014-5793(87)80065-0\nKao, 1984, J. Biol. Chem., 259, 11662, 10.1016\u002FS0021-9258(20)71257-3\nNeumann, 1986, 83, 3008\nMishina, 1985, Nature, 313, 364, 10.1038\u002F313364a0\nDennis, 1986, FEBS Lett., 207, 243, 10.1016\u002F0014-5793(86)81497-1\nNeher, 1978, J. Physiol. (London), 277, 153, 10.1113\u002Fjphysiol.1978.sp012267\nCohen, 1974, Mol. Pharmacol., 10, 904\nHeidmann, 1983, Biochemistry, 22, 3112, 10.1021\u002Fbi00282a014\nChangeux, 1986, J. Physiol. (London), 378, 497, 10.1113\u002Fjphysiol.1986.sp016232\nHeidmann, 1986, Biochemistry, 25, 6109, 10.1021\u002Fbi00368a041\nCox, 1985, J. Biol. Chem., 260, 7186, 10.1016\u002FS0021-9258(17)39592-3\nGiraudat, 1986, 83, 2719\nGiraudat, 1987, Biochemistry, 26, 2410, 10.1021\u002Fbi00383a003\nHucho, 1986, FEBS Lett., 205, 137, 10.1016\u002F0014-5793(86)80881-X\nHerz, 1987, J. Biol. Chem., 262, 7238, 10.1016\u002FS0021-9258(18)48229-4\nImoto, 1986, Nature, 324, 670, 10.1038\u002F324670a0\nFurois-Corbin, 1986, Biochim. Biophys. Acta, 860, 165, 10.1016\u002F0005-2736(86)90512-2\nMonod, 1965, J. Mol. Biol., 12, 88, 10.1016\u002FS0022-2836(65)80285-6\nJackson, 1984, 81, 3901\nChangeux, 1987, 549\nHökfelt, 1986, Prog. Brain Res., 68, 33, 10.1016\u002FS0079-6123(08)60230-7\nBoyd, 1987, J. Physiol. (London), 369, 69, 10.1113\u002Fjphysiol.1987.sp016647\nMiledi, 1980, 209, 447\nTakeyasu, 1986, Biochemistry, 25, 1770, 10.1021\u002Fbi00355a048\nHuganir, 1986, Nature, 321, 744, 10.1038\u002F321774a0\nRevah, 1987, 84, 3477\nFischer, 1986, 241\nAscher, 1987, Trends Neurosci., 10, 284, 10.1016\u002F0166-2236(87)90174-3\nGrenningloh, 1987, Nature, 328, 215, 10.1038\u002F328215a0\nSchofield, 1987, Nature, 328, 221, 10.1038\u002F328221a0\nMacCrea, P. D., Popat, J. L. and Engelman, D. H. EMBO J. (in press).",{"VOID":1549},"10.1016\u002F0165-6147(87)90039-3","2024-06-25T01:15:36.696+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0165614787900393",[1553,1578,1593],{"id":1554,"sortIndex":19,"researcher":18,"roles":1555,"affiliations":1556,"properties":1573,"displayName":1575,"givenName":18,"familyName":18},"857ad083-97e5-441d-a516-4884d8360eef",[119],[1557,1565],{"id":1558,"sortIndex":19,"affiliation":1559,"properties":18},"e2f2423b-2210-4661-8300-bd3352aee5c6",{"id":1558,"createTime":18,"updateTime":18,"relativeEntities":1560,"slug":18,"properties":1561,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1564,"statistic":18},[],{"title":1562},{"EN":1563},"Collège de France, France",[],{"id":1566,"sortIndex":136,"affiliation":1567,"properties":18},"f30300ec-2684-4823-a0e9-9af92eecbc5e",{"id":1566,"createTime":18,"updateTime":18,"relativeEntities":1568,"slug":18,"properties":1569,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1572,"statistic":18},[],{"title":1570},{"EN":1571},"Institut Pasteur, France",[],{"title":1574,"gsAuthor":1576},{"VI":1575},"Jean-Pierre Changeux",{"VOID":1577},"[\"Bq3F8iIAAAAJ\"]",{"id":1579,"sortIndex":136,"researcher":18,"roles":1580,"affiliations":1581,"properties":1590,"displayName":1592,"givenName":18,"familyName":18},"d501eee3-9d68-4646-ba7c-ef1c0f768b1e",[119],[1582],{"id":1583,"sortIndex":19,"affiliation":1584,"properties":18},"6156a7b8-0660-47c5-a8cf-9451ceda4846",{"id":1583,"createTime":18,"updateTime":18,"relativeEntities":1585,"slug":18,"properties":1586,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1589,"statistic":18},[],{"title":1587},{"VI":1588},"Centre National de la Recherche Scientifique, Unité de Neurobiologie Moléculaire, Unité Associée au Centre National de la Recherche Scientifique, UA 041149, Interactions Moléculaires et Cellulaires, Institut Pasteur, Départment des Biotechnologies, 25 rue du Dr Roux, 75724 Paris Cedex 15, France",[],{"title":1591},{"VI":1592},"Jérôme Giraudat",{"id":1594,"sortIndex":152,"researcher":18,"roles":1595,"affiliations":1596,"properties":1605,"displayName":1607,"givenName":18,"familyName":18},"cb9d407b-a76e-4b24-9910-a6766e289677",[119],[1597],{"id":1598,"sortIndex":19,"affiliation":1599,"properties":18},"b969bbf5-6462-42fc-80e2-7d2a648280a3",{"id":1598,"createTime":18,"updateTime":18,"relativeEntities":1600,"slug":18,"properties":1601,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1604,"statistic":18},[],{"title":1602},{"VI":1603},"Montreal, Canada",[],{"title":1606},{"VI":1607},"Michael Dennis",{"url":1551,"publisher":1609,"properties":1654},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1610,"slug":10,"properties":1611,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1614,"manageAffiliations":1623,"indexDatabases":1639,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1612,"title":1613},{"VOID":13},{"EN":15},[1615,1619],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1616,"label":1617,"description":1618,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1620,"label":1621,"description":1622,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[1624,1629,1634],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":1625,"slug":18,"properties":1626,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1628,"statistic":18},[],{"title":1627},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":1630,"slug":18,"properties":1631,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1633,"statistic":18},[],{"title":1632},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":1635,"slug":18,"properties":1636,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1638,"statistic":18},[],{"title":1637},{"EN":53},[],[1640,1647],{"id":57,"indexDatabase":1641,"url":70,"indexYears":18,"academicFieldIds":1646,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":1642,"label":1643,"description":1644,"key":66,"publicationTags":1645,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":1648,"url":85,"indexYears":86,"academicFieldIds":1653,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":1649,"label":1650,"description":1651,"key":82,"publicationTags":1652,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":1655,"volume":1657},{"VOID":1656},"459-465",{"VOID":1658},"8","1987-12-01",1987,"DONE_GET_PLATFORM_ID",[68,90],{"id":1664,"createTime":1665,"updateTime":1666,"relativeEntities":1667,"slug":1668,"properties":1669,"entityType":110,"verifyStatus":111,"verifyTime":1678,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1679,"fullTextUrl":18,"authors":1680,"publicationType":180,"publisherRelationship":1722,"citationCount":19,"citationInfo":1773,"publishDate":1776,"publishYear":1774,"citationAnalyzeStatus":1777,"lastCitationAnalyze":1666,"indexDatabases":1778,"openAccess":18,"references":18,"isForceReanalyzing":239},"dfafae02-5da3-4665-8157-b09e4921012d","2024-02-05T21:05:45.907+00:00","2026-07-26T20:37:32.783+00:00",[],"Prostanoid-receptor-signaling-relevant-to-tumor-growth-and-angiogenesis",{"title":1670,"gsPaper":1672,"references":1674,"doi":1676},{"EN":1671},"Prostanoid receptor signaling relevant to tumor growth and angiogenesis",{"VOID":1673},"[\"12789364174609016533\"]",{"VOID":1675},"Smalley, 1997, Colorectal cancer and non steroidal anti-inflammatory drugs, Adv. Pharmacol., 39, 1, 10.1016\u002FS1054-3589(08)60067-8\nKatori, 2000, Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors, Inflamm. Res., 49, 367, 10.1007\u002Fs000110050605\nGupta, 2001, Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2, Nat. Rev. Cancer, 1, 11, 10.1038\u002F35094017\nSubbaramaiah, 2003, Cyclooxygenase 2: a molecular target for cancer prevention and treatment, Trends Pharmacol. Sci., 24, 96, 10.1016\u002FS0165-6147(02)00043-3\nChandrasekharan, 2002, COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic\u002Fantipyretic drugs: cloning, structure, and expression, Proc. Natl. Acad. Sci. U. S. A., 99, 13926, 10.1073\u002Fpnas.162468699\nOhshima, 1996, Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2), Cell, 87, 803, 10.1016\u002FS0092-8674(00)81988-1\nDeWitt, 1999, Cox-2-selective inhibitors: the new super aspirins, Mol. Pharmacol., 55, 625\nOkumura, 2002, Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension, Hypertens. Res., 25, 927, 10.1291\u002Fhypres.25.927\nNorwood, 2000, Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice, Kidney Int., 58, 2291, 10.1046\u002Fj.1523-1755.2000.00413.x\nMarx, 2001, Anti-inflammatories inhibit cancer growth–but how?, Science, 291, 581, 10.1126\u002Fscience.291.5504.581\nPrescott, 1996, Self-promotion? Intimate connections between APC and prostaglandin H synthase-2, Cell, 87, 783, 10.1016\u002FS0092-8674(00)81983-2\nShiff, 1997, Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions, Gastroenterology, 113, 1992, 10.1016\u002FS0016-5085(97)99999-6\nNarumiya, 1999, Prostanoid receptors: structures, properties, and function, Physiol. Rev., 79, 1193, 10.1152\u002Fphysrev.1999.79.4.1193\nYang, 2003, Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor, J. Clin. Invest., 111, 727, 10.1172\u002FJCI16492\nNguyen, 1997, The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth, Nature, 390, 78, 10.1038\u002F36342\nWatanabe, 1999, Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis, Cancer Res., 59, 5093\nSonoshita, 2001, Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta716) knockout mice, Nat. Med., 7, 1048, 10.1038\u002Fnm0901-1048\nSeno, 2002, Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps, Cancer Res., 62, 506\nAmano, 2003, Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth, J. Exp. Med., 197, 221, 10.1084\u002Fjem.20021408\nHanahan, 1996, Patterns and emerging mechanisms of angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016\u002FS0092-8674(00)80108-7\nKitamura, 2002, Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis, Carcinogenesis, 23, 1463, 10.1093\u002Fcarcin\u002F23.9.1463\nChulada, 2000, Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice, Cancer Res., 60, 4705\nDormond, 2001, NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42\u002FRac-dependent endothelial-cell spreading, migration and angiogenesis, Nat. Med., 7, 1041, 10.1038\u002Fnm0901-1041\nDormond, 2002, Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP\u002FPKA-dependent signaling, J. Biol. Chem., 277, 45838, 10.1074\u002Fjbc.M209213200\nTsujii, 1998, Cyclooxygenase regulates angiogenesis induced by colon cancer cells, Cell, 93, 705, 10.1016\u002FS0092-8674(00)81433-6\nZiche, 1982, Role of prostaglandin E1 and copper in angiogenesis, J. Natl. Cancer Inst., 69, 475\nSpisni, 1992, Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors, Prostaglandins Leukot. Essent. Fatty Acids, 47, 111, 10.1016\u002F0952-3278(92)90146-A\nForm, 1983, PGE2 and angiogenesis, Proc. Soc. Exp. Biol. Med., 172, 214, 10.3181\u002F00379727-172-41548\nKatada, 2002, Significance of vascular endothelial cell growth factor up-regulation mediated via a chymase-angiotensin-dependent pathway during angiogenesis in hamster sponge granulomas, J. Pharmacol. Exp. Ther., 302, 949, 10.1124\u002Fjpet.102.034231\nMuramatsu, 2000, Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model, J. Biol. Chem., 275, 5545, 10.1074\u002Fjbc.275.8.5545\nHayashi, 2002, Suppressed angiogenesis in kininogen-deficiencies, Lab. Invest., 82, 871, 10.1097\u002F01.LAB.0000018885.36823.D6\nMajima, 2000, Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants, Br. J. Pharmacol., 130, 641, 10.1038\u002Fsj.bjp.0703327\nMajima, 1997, Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants, Jpn. J. Pharmacol., 75, 105, 10.1016\u002FS0021-5198(19)31321-6\nAmano, 2001, Adenylate cyclase\u002Fprotein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo, Jpn. J. Pharmacol., 87, 181, 10.1254\u002Fjjp.87.181\nMurata, 1997, Altered pain perception and inflammatory responses in mice lacking prostacyclin receptor, Nature, 388, 678, 10.1038\u002F41780\nSugimoto, 1997, Failure of parturition in mice lacking the prostaglandin F receptor, Science, 277, 681, 10.1126\u002Fscience.277.5326.681\nSegi, 1998, Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice, Biochem. Biophys. Res. Commun., 246, 7, 10.1006\u002Fbbrc.1998.8461\nUshikubi, 1998, Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3, Nature, 395, 281, 10.1038\u002F26233\nHizaki, 1999, Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2, Proc. Natl. Acad. Sci. U. S. A., 96, 10501, 10.1073\u002Fpnas.96.18.10501\nMatsuoka, 2000, Prostaglandin D2 as a mediator of allergic asthma, Science, 287, 2013, 10.1126\u002Fscience.287.5460.2013\nWatanabe, 2000, Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice, Cancer Lett., 156, 57, 10.1016\u002FS0304-3835(00)00440-7\nSuzawa, 2000, The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for respective EPs, Endocrinology, 141, 1554, 10.1210\u002Fendo.141.4.7405\nKabashima, 2002, The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut, J. Clin. Invest., 109, 883, 10.1172\u002FJCI0214459\nZweifel, 2002, Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors, Cancer Res., 62, 6706\nBen-Av, 1995, Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis, FEBS Lett., 372, 83, 10.1016\u002F0014-5793(95)00956-A\nMutoh, 2002, Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis, Cancer Res., 62, 28\nLiu, 2002, Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line, J. Biol. Chem., 277, 50081, 10.1074\u002Fjbc.M201095200\nFukuda, 2003, Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1, Cancer Res., 63, 2330\nSmith, 1995, Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts, J. Clin. Endocrinol. Metab., 80, 2620\nGoldring, 1990, Heterogeneity in hormone responses and patterns of collagen synthesis in cloned dermal fibroblasts, J. Clin. Invest., 85, 798, 10.1172\u002FJCI114506\nKo, 1977, Fibroblast heterogeneity and prostaglandin regulation of subpopulations, Proc. Natl. Acad. Sci. U. S. A., 74, 3429, 10.1073\u002Fpnas.74.8.3429\nFukumura, 1997, Effect of host microenvironment on the microcirculation of human colon adenocarcinoma, Am. J. Pathol., 151, 679\nGohongi, 1999, Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta, Nat. Med., 5, 1203, 10.1038\u002F13524\nSano, 1995, Expression of cyclooxygenase-1 and -2 in human colorectal cancer, Cancer Res., 55, 3785\nWilliams, 2000, Host cyclooxygenase-2 modulates carcinoma growth, J. Clin. Invest., 105, 1589, 10.1172\u002FJCI9621\nCoussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038\u002Fnature01322\nMantovani, 2002, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol., 23, 549, 10.1016\u002FS1471-4906(02)02302-5\nDe Palma, 2003, Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells, Nat. Med., 9, 789, 10.1038\u002Fnm871\nGreenlee, 2000, Cancer statistics, 2000, CA Cancer J. Clin., 50, 7, 10.3322\u002Fcanjclin.50.1.7\nSheng, 2001, Prostaglandin E2 increases growth and motility of colorectal carcinoma cells, J. Biol. Chem., 276, 18075, 10.1074\u002Fjbc.M009689200\nSchirner, 1997, Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth, Cancer Detect. Prev., 21, 44",{"VOID":1677},"10.1016\u002Fj.tips.2003.08.005","2024-06-25T00:10:33.844+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0165614703002608",[1681,1696,1709],{"id":1682,"sortIndex":19,"researcher":18,"roles":1683,"affiliations":1684,"properties":1693,"displayName":1695,"givenName":18,"familyName":18},"1f815c76-bf05-4e22-8c75-1d0378f43783",[119],[1685],{"id":1686,"sortIndex":19,"affiliation":1687,"properties":18},"987c9d31-1b5a-4bc6-a741-d4ae9d96b6b1",{"id":1686,"createTime":18,"updateTime":18,"relativeEntities":1688,"slug":18,"properties":1689,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1692,"statistic":18},[],{"title":1690},{"VI":1691},"Department of Pharmacology, Kitasato University School of Medicine, Kitasato 1-15-1, Sagamihara, Kanagawa 228-8555, Japan",[],{"title":1694},{"VI":1695},"Masataka Majima",{"id":1697,"sortIndex":136,"researcher":18,"roles":1698,"affiliations":1699,"properties":1706,"displayName":1708,"givenName":18,"familyName":18},"851365e3-9cd2-4617-b93a-64827f8d16d8",[119],[1700],{"id":1686,"sortIndex":19,"affiliation":1701,"properties":18},{"id":1686,"createTime":18,"updateTime":18,"relativeEntities":1702,"slug":18,"properties":1703,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1705,"statistic":18},[],{"title":1704},{"VI":1691},[],{"title":1707},{"VI":1708},"Hideki Amano",{"id":1710,"sortIndex":152,"researcher":18,"roles":1711,"affiliations":1712,"properties":1719,"displayName":1721,"givenName":18,"familyName":18},"d1d2d963-7666-4c3a-b69c-9cbc66d01531",[119],[1713],{"id":1686,"sortIndex":19,"affiliation":1714,"properties":18},{"id":1686,"createTime":18,"updateTime":18,"relativeEntities":1715,"slug":18,"properties":1716,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1718,"statistic":18},[],{"title":1717},{"VI":1691},[],{"title":1720},{"VI":1721},"Izumi Hayashi",{"url":1679,"publisher":1723,"properties":1768},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1724,"slug":10,"properties":1725,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1728,"manageAffiliations":1737,"indexDatabases":1753,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1726,"title":1727},{"VOID":13},{"EN":15},[1729,1733],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1730,"label":1731,"description":1732,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1734,"label":1735,"description":1736,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[1738,1743,1748],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":1739,"slug":18,"properties":1740,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1742,"statistic":18},[],{"title":1741},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":1744,"slug":18,"properties":1745,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1747,"statistic":18},[],{"title":1746},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":1749,"slug":18,"properties":1750,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1752,"statistic":18},[],{"title":1751},{"EN":53},[],[1754,1761],{"id":57,"indexDatabase":1755,"url":70,"indexYears":18,"academicFieldIds":1760,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":1756,"label":1757,"description":1758,"key":66,"publicationTags":1759,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":1762,"url":85,"indexYears":86,"academicFieldIds":1767,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":1763,"label":1764,"description":1765,"key":82,"publicationTags":1766,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":1769,"volume":1771},{"VOID":1770},"524-529",{"VOID":1772},"24",{"total":19,"publishYear":1774,"statisticByYear":1775},2003,{},"2003-10-01","DONE_ANALYZE_CITATION",[68,90],{"id":1780,"createTime":1781,"updateTime":1782,"relativeEntities":1783,"slug":1784,"properties":1785,"entityType":110,"verifyStatus":111,"verifyTime":1794,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1795,"fullTextUrl":18,"authors":1796,"publicationType":180,"publisherRelationship":1814,"citationCount":19,"citationInfo":1864,"publishDate":1866,"publishYear":1774,"citationAnalyzeStatus":17,"lastCitationAnalyze":1782,"indexDatabases":1867,"openAccess":18,"references":18,"isForceReanalyzing":239},"dc9f2b14-19e6-47f1-80fe-f9887f526895","2023-12-13T08:13:09.619+00:00","2026-07-22T12:46:07.376+00:00",[],"Advancing-towards-a-male-contraceptive-a-novel-approach-from-an-unexpected-direction",{"title":1786,"gsPaper":1788,"references":1790,"doi":1792},{"EN":1787},"Advancing towards a male contraceptive: a novel approach from an unexpected direction",{"VOID":1789},"[\"1492822309392523581\"]",{"VOID":1791},"Anderson, 2002, Male contraception, Endocr. Rev., 23, 735, 10.1210\u002Fer.2002-0002\nTurner, 1991, Spermatozoa are exposed to a complex microenvironment as they traverse the epididymis, Ann. New York Acad. Sci., 637, 364, 10.1111\u002Fj.1749-6632.1991.tb27323.x\nZirkin, 1989, Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis, Endocrinology, 124, 3043, 10.1210\u002Fendo-124-6-3043\nLobl, 1983, Contraceptive efficacy of testosterone-estradiol implants in male rhesus monkeys, Contraception, 27, 383, 10.1016\u002FS0010-7824(83)80017-1\nvan Houten, 2000, Differences in reproductive endocrinology between Asian men and Caucasian men, Asian J. Androl., 2, 13\nEwing, 1977, Synergistic interaction of testosterone and oestradiol inhibits spermatogenesis in rats, Nature, 269, 409, 10.1038\u002F269409a0\nKamischke, 2001, Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception, J. Clin. Endocrinol. Metab., 86, 303, 10.1210\u002Fjc.86.1.303\nMcLachlan, 2002, Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men, J. Clin. Endocrinol. Metab., 87, 546, 10.1210\u002Fjc.87.2.546\nRamachandra, 2002, Effect of chronic administration of 7alpha-methyl-19-nortestosterone on serum testosterone, number of spermatozoa and fertility in adult male bonnet monkeys (Macaca radiata), Reproduction, 124, 301, 10.1530\u002Frep.0.1240301\nJackson, 1979, Contraception for the male: problems with progress, Clin. Obstet. Gynaecol., 6, 129, 10.1016\u002FS0306-3356(21)00451-9\nLiu, G.Z. et al. (1985) Trials of gossypol as a male contraceptive. In Gossypol: A Potential Contraceptive for Men (Segal, S., ed.), pp. 9–16, Plenum Publishers.\nZavos, 1996, The inhibitory effects of gossypol on human sperm motility characteristics: possible modes of reversibility of those effects, Tohoku J. Exp. Med., 179, 167, 10.1620\u002Ftjem.179.167\nLiu, 1988, Effects of K salt or a potassium blocker on gossypol-related hypokalemia, Contraception, 37, 111, 10.1016\u002F0010-7824(88)90121-7\nShi, 2003, Ion-channels in human sperm membrane and contraceptive mechanisms of male antifertility compounds derived from Chinese traditional medicine, Acta Pharmacol. Sin., 24, 22\nCheng, 2002, Indazole carboxylic acids in male contraception, Contraception, 65, 265, 10.1016\u002FS0010-7824(01)00318-3\nCooper, T.G. (2002) The epididymis as a target for male contraception. In The Epididymis: From Molecules to Clinical Practice (Robaire, B. and Hinton, B.T., eds), pp. 483–502, Kluwer Academic Plenum Publishers.\nFrayne, 1999, The potential use of sperm antigens as targets for immunocontraception; past, present and future, J. Reprod. Immunol., 43, 1, 10.1016\u002FS0165-0378(99)00005-4\nRen, 2001, A sperm ion channel required for sperm motility and male fertility, Nature, 413, 603, 10.1038\u002F35098027\nvan der Spoel, 2002, Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception, Proc. Natl. Acad. Sci. U. S. A., 99, 17173, 10.1073\u002Fpnas.262586099\nButters, 2003, Therapeutic applications of imino sugars in lysosomal storage disorders, Curr. Top. Med. Chem., 3, 561, 10.2174\u002F1568026033452483\nPlatt, 2001, Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy, J. Inherit. Metab. Dis., 24, 275, 10.1023\u002FA:1010335505357\nCox, 2000, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, Lancet, 355, 1481, 10.1016\u002FS0140-6736(00)02161-9\nTrasler, 1998, Characterization of the testis and epididymis in mouse models of human Tay Sachs and Sandhoff diseases and partial determination of accumulated gangliosides, Endocrinology, 139, 3280, 10.1210\u002Fen.139.7.3280\nFujimoto, 2000, Requirement of seminolipid in spermatogenesis revealed by UDP-galactose: Ceramide galactosyltransferase-deficient mice, J. Biol. Chem., 275, 22623, 10.1074\u002Fjbc.C000200200\nWhite, 2000, Role of sperm sulfogalactosylglycerolipid in mouse sperm-zona pellucida binding, Biol. Reprod., 63, 147, 10.1095\u002Fbiolreprod63.1.147",{"VOID":1793},"10.1016\u002Fs0165-6147(03)00141-x","2024-05-15T03:02:21.218+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS016561470300141X",[1797],{"id":1798,"sortIndex":19,"researcher":18,"roles":1799,"affiliations":1800,"properties":1809,"displayName":1811,"givenName":18,"familyName":18},"717254f3-b169-4763-8ce3-1273ea6fe827",[119],[1801],{"id":1802,"sortIndex":19,"affiliation":1803,"properties":18},"79854d8c-9410-4022-a4de-1e409de855c9",{"id":1802,"createTime":18,"updateTime":18,"relativeEntities":1804,"slug":18,"properties":1805,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1808,"statistic":18},[],{"title":1806},{"VI":1807},"Department of Pharmacology and Therapeutics and of Obstetrics and Gynecology, McGill University, Montréal, QC H3G 1Y6, Canada",[],{"title":1810,"gsAuthor":1812},{"VI":1811},"Bernard Robaire",{"VOID":1813},"[\"faHqEpcAAAAJ\"]",{"url":1795,"publisher":1815,"properties":1860},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1816,"slug":10,"properties":1817,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1820,"manageAffiliations":1829,"indexDatabases":1845,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1818,"title":1819},{"VOID":13},{"EN":15},[1821,1825],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1822,"label":1823,"description":1824,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1826,"label":1827,"description":1828,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[1830,1835,1840],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":1831,"slug":18,"properties":1832,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1834,"statistic":18},[],{"title":1833},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":1836,"slug":18,"properties":1837,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1839,"statistic":18},[],{"title":1838},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":1841,"slug":18,"properties":1842,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1844,"statistic":18},[],{"title":1843},{"EN":53},[],[1846,1853],{"id":57,"indexDatabase":1847,"url":70,"indexYears":18,"academicFieldIds":1852,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":1848,"label":1849,"description":1850,"key":66,"publicationTags":1851,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":1854,"url":85,"indexYears":86,"academicFieldIds":1859,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":1855,"label":1856,"description":1857,"key":82,"publicationTags":1858,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":1861,"volume":1863},{"VOID":1862},"326-328",{"VOID":1772},{"total":19,"publishYear":1774,"statisticByYear":1865},{},"2003-07-01",[68,90],{"id":1869,"createTime":1870,"updateTime":1871,"relativeEntities":1872,"slug":1873,"properties":1874,"entityType":110,"verifyStatus":111,"verifyTime":1883,"verifyNote":113,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1884,"fullTextUrl":18,"authors":1885,"publicationType":180,"publisherRelationship":1904,"citationCount":18,"citationInfo":18,"publishDate":1955,"publishYear":1956,"citationAnalyzeStatus":17,"lastCitationAnalyze":1957,"indexDatabases":1958,"openAccess":18,"references":18,"isForceReanalyzing":239},"2a79c36a-4ebe-4477-8163-b038a04b4e06","2023-12-29T09:18:22.471+00:00","2026-07-22T09:52:36.736+00:00",[],"New-bombesin-antagonist-shown-to-have-encouraging-profile-",{"title":1875,"gsPaper":1877,"references":1879,"doi":1881},{"EN":1876},"New bombesin antagonist shown to have ‘encouraging profile’",{"VOID":1878},"[\"3801059856623615222\"]",{"VOID":1880},"Anastasi, 1977, Experientia, 27, 166, 10.1007\u002FBF02145873\nPanula, 1986, Med. Biol., 64, 177\nErspamer, 1983, Vol. 2, 37\nMartinez, 1985, J. Med. Chem., 28, 1874, 10.1021\u002Fjm00150a020\nSasaki, 1987, J. Med. Chem., 30, 1162, 10.1021\u002Fjm00390a008\nGreen, 1987, Trends Pharmacol. Sci., 8, 90, 10.1016\u002F0165-6147(87)90081-2\nCoy, D. H., Heinz-Erian, P., Jiang, N-Y., Taylor, J., Moreau, J-P., Gardner J. D. and Jensen, R. T. Ann. N.Y. Acad. Sci., (in press).",{"VOID":1882},"10.1016\u002F0165-6147(88)90227-1","2024-06-26T22:37:08.278+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0165614788902271",[1886],{"id":1887,"sortIndex":19,"researcher":18,"roles":1888,"affiliations":1889,"properties":1901,"displayName":1903,"givenName":18,"familyName":18},"b975ba9b-3faf-4b05-b637-47b21ef788ca",[119],[1890],{"id":1891,"sortIndex":19,"affiliation":1892,"properties":1898},"86e6e676-6c1a-4435-841e-80de95f723c1",{"id":1891,"createTime":18,"updateTime":18,"relativeEntities":1893,"slug":18,"properties":1894,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1897,"statistic":18},[],{"title":1895},{"VI":1896},"Department of Pharmacology, Temple University School of Medicine Philadelphia, PA 19140 USA",[],{"title":1899},{"VI":1900},"Department of Pharmacology Temple University School of Medicine Philadelphia, PA 19140, USA",{"title":1902},{"VI":1903},"Alan Cowan",{"url":1884,"publisher":1905,"properties":1950},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1906,"slug":10,"properties":1907,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1910,"manageAffiliations":1919,"indexDatabases":1935,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1908,"title":1909},{"VOID":13},{"EN":15},[1911,1915],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1912,"label":1913,"description":1914,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1916,"label":1917,"description":1918,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},[1920,1925,1930],{"id":35,"createTime":18,"updateTime":18,"relativeEntities":1921,"slug":18,"properties":1922,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1924,"statistic":18},[],{"title":1923},{"EN":39},[],{"id":42,"createTime":18,"updateTime":18,"relativeEntities":1926,"slug":18,"properties":1927,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1929,"statistic":18},[],{"title":1928},{"EN":46},[],{"id":49,"createTime":18,"updateTime":18,"relativeEntities":1931,"slug":18,"properties":1932,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1934,"statistic":18},[],{"title":1933},{"EN":53},[],[1936,1943],{"id":57,"indexDatabase":1937,"url":70,"indexYears":18,"academicFieldIds":1942,"indexDatabaseRanking":18},{"id":59,"createTime":18,"updateTime":18,"relativeEntities":1938,"label":1939,"description":1940,"key":66,"publicationTags":1941,"standard":18},[],{"EN":62,"VI":62},{"EN":64,"VI":65},[68,69],[72],{"id":74,"indexDatabase":1944,"url":85,"indexYears":86,"academicFieldIds":1949,"indexDatabaseRanking":90},{"id":76,"createTime":18,"updateTime":18,"relativeEntities":1945,"label":1946,"description":1947,"key":82,"publicationTags":1948,"standard":18},[],{"EN":79,"VI":79},{"EN":79,"VI":81},[84],[88,89],{"pages":1951,"volume":1953},{"VOID":1952},"1-3",{"VOID":1954},"9","1988-01-01",1988,"2026-07-22T09:52:36.735+00:00",[68,90]]